cisapride has been researched along with Gastroesophageal Reflux in 254 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro-oesophageal reflux disease." | 9.10 | Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. ( Gardner, JD; Miner, PB; Robinson, M; Rodriguez-Stanley, S, 2002) |
| "To evaluate the efficiency of the 5-HT4 agonist and 5-HT3 antagonist mosapride, as compared with cisapride, on oesophageal acid reflux variables and oesophageal motor function in patients with chronic gastro-oesophageal reflux disease (GORD)." | 9.10 | The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. ( Cange, L; Finizia, C; Lundell, L; Ruth, M, 2003) |
| "To evaluate the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastro-oesophageal reflux." | 9.10 | The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease. ( Cange, L; Finizia, C; Lundell, L; Ruth, M, 2002) |
| "To investigate the effect of cisapride, a selective 5-hydroxytryptamine-4 receptor agonist, on the frequency of nocturnal transient lower oesophageal sphincter relaxations and oesophageal acid exposure in patients with gastro-oesophageal reflux disease." | 9.10 | Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. ( McCallum, R; Olyaee, M; Pehlivanov, N; Sarosiek, I; Whitman, R, 2002) |
| "To evaluate the efficacy of cisapride in the treatment of uncomplicated gastroesophageal reflux in children younger than 36 months of age." | 9.09 | Cisapride in the control of symptoms in infants with gastroesophageal reflux: A randomized, double-blind, placebo-controlled trial. ( Cohen, RC; Davidson, GP; Lawrence, DM; Moore, DJ; O'Loughlin, EV, 1999) |
| "To investigate the pharmacokinetics of enterally administered cisapride suspension in young infants being treated for gastro-oesophageal reflux disease." | 9.09 | Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. ( Charles, B; Donovan, T; Piotrovskij, V; Preechagoon, Y; Van Peer, A, 1999) |
| "This study was conducted to assess the efficacy of a novel 40-mg extended-release formulation of cisapride in reducing gastro-oesophageal reflux." | 9.09 | The efficacy of a 40-mg extended-release formulation of cisapride in the treatment of patients with gastro-oesophageal reflux. ( Arnold, R; Katschinski, M; Schirra, J, 2000) |
| "Enhanced gastric functioning and reduction in heartburn suggest that cisapride is efficacious in the treatment of older adults with symptomatic GERD, and that gastric dysrhythmias and postprandial fullness are resolved with cisapride treatment." | 9.09 | Gastric myoelectric activity in older adults treated with cisapride for gastro-oesophageal reflux disease. ( Chen, JD; McClanahan, J; Orr, WC; Sloan, S; Zhang, M, 2000) |
| "Gastrointestinal prokinetic agents, such as cisapride, are commonly used in pediatric practice to improve gastric emptying, to decrease emesis, to improve lower esophageal sphincter tone, and to improve irritability and feeding aversion associated with gastroesophageal reflux (GER)." | 9.09 | Cisapride decreases gastroesophageal reflux in preterm infants. ( Ariagno, RL; Baldwin, RB; Conrad, C; Kikkert, MA; Mirmiran, M, 2001) |
| "To study prospectively the effects of cisapride on ventricular repolarization, depolarization, and arrhythmia markers in neonates, we determined before and three days after starting cisapride (1 mg/kg/day): corrected QT interval (QTc) and QT dispersion (QTd) on standard ECGs, and duration of filtered QRS (fQRS) and of low amplitude (<40 microV) terminal signals (LAS40, ms) and root mean square of the last 40 ms (RMS40, microV) using high-gain signal-averaged ECG (SAECG)." | 9.09 | Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants. ( Belli, DC; Ferrazzini, G; Friedli, B; Zamora, SA, 2001) |
| "Cisapride and ranitidine improved the symptoms of diffuse epigastric pain, postprandial epigastric fullness, epigastric distension, belching, heartburn, regurgitation, and nausea when compared with baseline." | 9.08 | Cisapride compared with ranitidine in the treatment of functional dyspepsia. ( Carvalhinhos, A; Fidalgo, P; Freire, A; Matos, L, 1995) |
| "To evaluate the safety and efficacy of cisapride in patients with gastroesophageal reflux disease." | 9.08 | Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. ( Long, JF; Richter, JE, 1995) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 9.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| " The aim of this study was to look at duodenal reflux in the oesophagus together with motility characteristics in a group of patients with Barrett's oesophagus and compare them with a mild oesophagitis group and to assess the effect of cisapride on any abnormalities." | 9.08 | Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus. ( Bird, NC; Globe, J; Johnson, AG; Smythe, A; Troy, GP, 1997) |
| "We evaluated the efficacy and safety of a twice-daily dosage regimen of cisapride 20 mg in relieving the symptoms of mild-moderate gastroesophageal reflux disease (GERD) in patients with moderate intensity heartburn and no history of erosive esophagitis." | 9.08 | Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. ( Castell, DO; Clyde, C; Hasner, D; Lambert, R; Patterson, D; Sigmund, C; Zeldis, JB, 1998) |
| "Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q." | 9.07 | Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. ( Anthopoulou, H; Arvanitakis, C; Giannoulis, E; Michailidis, D; Nikopoułos, A; Theoharidis, A; Tourkantonis, A; Vagios, I, 1993) |
| "The efficacy and tolerability of Cisapride effervescent granules for treatment of gastroesophageal reflux disease were compared to a metoclopramide-dimeticone combination." | 9.07 | [A new granular effervescent 10-mg formulation of cisapride in the treatment of gastroesophageal reflux]. ( Di Felice, F; Grossi, L; Marzio, L, 1993) |
| "We compared the efficacy of the prokinetic agent cisapride with that of Gaviscon (an alginate/alkaline compound) plus Carobel (carob seed flour) in the treatment of gastrooesophageal reflux (GOR)." | 9.07 | Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. ( Greally, P; Hampton, FJ; MacFadyen, UM; Simpson, H, 1992) |
| "Controlled studies showed that cisapride is effective in non-ulcer dyspepsia." | 9.07 | [Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms]. ( Fehr, HF, 1991) |
| "The effect of cisapride, a new gastrointestinal prokinetic drug, on oesophageal motility and acid reflux was studied in 14 children with gastro-oesophageal reflux disease, receiving either placebo or cisapride 0." | 9.06 | Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. ( Boccieri, A; Camerlingo, F; Capozzi, C; Cucchiara, S; De Stefano, M; Manzi, G; Paone, FM; Staiano, A, 1990) |
| "The influence of Cisapride on food-stimulated gastro-oesophageal reflux mechanisms was studied in a double-blind cross-over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro-oesophageal reflux and 12 with additional macroscopic oesophagitis." | 9.06 | Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study. ( Aksglade, K; Funch-Jensen, P; Gelineck, J; Thommesen, P, 1990) |
| "In a double-blind, randomized, comparative trial of the prokinetic drug cisapride and the H2-blocker cimetidine, mucosal healing and changes in symptoms of gastroesophageal reflux were evaluated in patients with erosive reflux esophagitis." | 9.06 | Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. ( Evreux, M; Filoche, B; Fournet, J; Fraitag, B; Galmiche, JP; Soule, JC; Vitaux, J; Zeitoun, P, 1990) |
| "We studied the effect of cisapride on oesophageal motor function and postprandial gastro-oesophageal reflux in a randomised, double blind, placebo controlled crossover study." | 9.06 | Effect of cisapride on postprandial gastro-oesophageal reflux. ( Dent, J; Downton, J; Holloway, RH; Mitchell, B, 1989) |
| "Since gastro-oesophageal reflux disease is due to disturbances of oesophageal motility, motor and pH measurements are an important means to test a new anti-reflux drug, cisapride." | 9.06 | Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. ( Li, Q; Wienbeck, M, 1989) |
| "In a double-blind, randomized study, the clinical effects of 5 mg and 10 mg of cisapride three times daily were compared with those of 10 mg of metoclopramide three times daily in 114 patients with symptoms of gastroesophageal reflux, mainly diurnal and nocturnal heartburn and regurgitation." | 9.06 | Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. ( Arabehety, JT; Fassler, S; Leitão, OR; Olarte, M; Serrano, C, 1988) |
| " Nine trials compared cisapride with placebo or no treatment, of which eight (262 participants) reported data on symptoms of gastro-oesophageal reflux." | 8.86 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Cash-Gibson, L; Gilbert, RE; Logan, S; Maclennan, S, 2010) |
| "No clinically important benefits of cisapride in children with gastroesophageal reflux have been demonstrated." | 8.82 | Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children. ( Craig, JC; Dalby-Payne, JR; Morris, AM, 2003) |
| " Eight trials compared Cisapride with placebo, of which seven (236 participants) reported data on symptoms of gastro-oesophageal reflux, and one reported data on the QTc interval (49 patients)." | 8.82 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2003) |
| " Eight trials compared Cisapride with placebo, of which seven (236 participants) reported data on symptoms of gastro-oesophageal reflux, and one reported data on the QTc interval (49 patients)." | 8.81 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2002) |
| "The prokinetic drug cisapride is widely used for treating gastro-oesophageal reflux in infants and children." | 8.80 | [Cisapride treatment for children with gastro-esophageal reflux]. ( Hoekstra, JH; Kneepkens, CM; Vandenplas, Y, 1999) |
| "The aim of the systematic review was to determine the effect of cisapride compared with placebo or other non-surgical therapies for the treatment of symptoms of gastro-oesophageal reflux in children." | 8.80 | Cisapride treatment for gastro-oesophageal reflux in children: a systematic review of randomized controlled trials. ( Augood, C; Gilbert, RE; Logan, S; MacLennan, S, 2000) |
| "Several studies have clearly demonstrated that omeprazole is highly efficacious in the management of patients with gastro-oesophageal reflux disease." | 8.77 | Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole? ( Klinkenberg-Knol, EC; Meuwissen, SG, 1989) |
| "Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves." | 7.76 | Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review. ( Richter, JE, 1989) |
| "We reviewed the medical records of all infants cisapride or metoclopramide in association with apnea." | 7.71 | Gastroesophageal reflux medications in the treatment of apnea in premature infants. ( Carlton, DP; Kimball, AL, 2001) |
| " The questionnaire was designed to evaluate the knowledge of the physician regarding the treatment of gastroesophageal reflux disease and the use of cisapride in children (indications, dosages, duration of treatment, limitations in certain age groups, the need for pretreatment laboratory tests, interactions with other drugs, and contraindications)." | 7.71 | Comparison between pediatricians and family practitioners in the use of the prokinetic cisapride for gastroesophageal reflux disease in children. ( Jaffe, M; Shahory, R; Shaoul, R; Tamir, A, 2002) |
| "Apnea in the neonatal period frequently is associated with prematurity." | 7.70 | Gastric ulcer presenting as gastroesophageal reflux and apnea in a term neonate. ( Biskinis, EK; Naqvi, M; Skinner, S, 1998) |
| "The objective of this study was to compare the neonatal postoperative course and morbidity for patients with gastroschisis who received cisapride with those who did not receive cisapride." | 7.70 | Cisapride and caesarean section: their role in babies with gastroschisis. ( Duffy, B; Kumar, RK; Shi, EC, 1999) |
| "We prospectively studied the effect of cisapride per se on QT interval in young infants (3-6 months) with gastroesophageal reflux (GER) in a controlled setting." | 7.70 | Effect of cisapride on the QT interval in infants with gastroesophageal reflux. ( Clarke, R; Edell, D; Khoshoo, V, 2000) |
| "Cisapride is frequently used in the newborn and infant for treatment of gastroesophageal reflux." | 7.69 | [Long QT syndrome under cisapride in neonates and infants]. ( Aujard, Y; Bedu, A; Casasoprana, A; Cézard, JP; Denjoy, I; Faure, C; Lupoglazoff, JM, 1997) |
| "To evaluate the effectiveness of administration of oral cisapride in patients with gastro-esophageal reflux, we studied 25 children, aged 1 month-7 years (mean 16." | 7.68 | [Evaluation of the effectiveness of cisapride in the treatment of gastroesophageal reflux]. ( Balsamo, V; Carroccio, A; Cavataio, F; Iacono, G; Kazmierska, I; Lorello, D; Montalto, G; Soresi, M, 1992) |
| "Cisapride was used to treat gastro-oesophageal reflux in seven children with neurodevelopmental disorders and in 15 children who were neurologically normal." | 7.68 | The effects of cisapride on gastro-oesophageal reflux in children with and without neurological disorders. ( Brueton, MJ; Clarke, GS; Sandhu, BK, 1990) |
| "We studied the effects of positional treatment and cisapride (a new prokinetic agent) on the incidence and duration of gastroesophageal reflux in 22 infants (4-26 weeks old) in asleep, awake, fasted, and postcibal periods." | 7.67 | Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: treatment with cisapride. ( Aerts, T; Deneyer, M; Sacre, L; Vandenplas, Y; Verlinden, M, 1989) |
| "Cisapride was previously used in the same indication." | 6.74 | Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. ( Advani, N; Alatas, S; Firmansyah, A; Hegar, B; Vandenplas, Y, 2009) |
| " A randomized, double-blind, placebo-controlled, three-period incomplete crossover design was used with three dosing periods of 7 days." | 6.69 | The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. ( Samsom, M; Smout, AJ; Van Herwaarden, MA; Van Nispen, CH; Verlinden, M, 2000) |
| "Medical treatment of duodenogastroesophageal reflux in postgastrectomy patients has been disappointing." | 6.68 | Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. ( Richter, JE; Sears, R; Vaezi, MF, 1996) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 6.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Cisapride is a safe, well tolerated prokinetic agent that improves the esophageal clearance of refluxed gastric acid in children under the age of 2 years." | 6.68 | Cisapride in pediatric gastroesophageal reflux. ( Ferreira, C; Jones, AB; Lohoues, MJ; Machida, H; Roy, CC; Scott, RB; Smith, L, 1997) |
| "Cisapride has well-documented prokinetic effects and may be well suited for long-term therapy of GORD, but its effectiveness in purely symptomatic treatment is unknown." | 6.68 | The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. ( Carling, L; Hatlebakk, JG; Johnsson, F; Thøgersen, T; Vilien, M; Wetterhus, S, 1997) |
| "Gastro-oesophageal reflux was very variable on both 24-h pH monitoring and acid reflux provocation test." | 6.67 | Cisapride in the treatment of gastro-oesophageal reflux disease. ( Atkinson, M; Evans, DF; Ledingham, SJ; Robertson, CS, 1993) |
| "Some patients with gastro-oesophageal reflux disease have delayed gastric emptying." | 6.67 | Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. ( Collins, PJ; Jamieson, GG; Maddern, GJ; Myers, JC, 1991) |
| "Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry." | 6.66 | Cisapride for gastro-oesophageal reflux and peptic oesophagitis. ( Auricchio, S; Boccieri, A; Capozzi, C; Cucchiara, S; Di Lorenzo, C; Staiano, A, 1987) |
| "Gastro-oesophageal reflux (GOR) is an extremely common and usually self limiting condition in infants." | 6.41 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2000) |
| "Cisapride is a gastrointestinal prokinetic agent that is used worldwide in the treatment of gastrointestinal motility-related disorders in premature infants, full-term infants, and children." | 6.40 | The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. ( Belli, DC; Benatar, A; Cadranel, S; Cucchiara, S; Dupont, C; Gottrand, F; Hassall, E; Heymans, HS; Kearns, G; Kneepkens, CM; Koletzko, S; Milla, P; Polanco, I; Staiano, AM; Vandenplas, Y, 1999) |
| "Cisapride treatment was assigned to the patients with pathologic monitoring results at a dose of 0." | 5.32 | Gastroesophageal reflux in children with cerebral palsy: efficacy of cisapride. ( Aydogdu, S; Bozkurt, M; Serdaroglu, G; Tekgul, H; Tutuncuoglu, S, 2004) |
| " In conclusion, cisapride has a positive influence on GOR parameters during caffeine treatment without impairing the oral bioavailability or therapeutic effect of caffeine." | 5.31 | Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine. ( Baisch, HJ; Heimann, G; Kentrup, H; Kusenbach, G; Skopnik, H, 2000) |
| "Gastroesophageal reflux (GER) is very common in infants, especially in prematures and may be cause of gastrointestinal and cardiorespiratory symptoms." | 5.31 | [QTc interval in newborns with gastroesophageal reflux treated with cisapride and ranitidine]. ( Colli, A; Compagnoni, G; Introvini, P; Lista, G; Maestri, L; Massari, D; Menchini, M; Meroni, M; Porcelli, F, 2000) |
| " Linkage to cisapride was probable, promoted by high dosage and cisapride metabolism inhibition by ranitidine, but its plasma concentration was not measured." | 5.30 | [Syncope with long QT interval in a 39 day-old infant treated with cisapride]. ( Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997) |
| "Cisapride is a novel prokinetic agent that releases acetylcholine at the level of the myenteric plexus." | 5.30 | Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. ( Bityutskiy, LP; Goldin, GF; Marcinkiewicz, M; McCallum, RW; Sarosiek, J; Zbroch, T, 1997) |
| "We evaluated the prevalence of gastroesophageal reflux in 36 children, 22 (61." | 5.29 | Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. ( Fontana, R; Lami, CA; Novembre, E; Resti, M; Tucci, F; Vierucci, A, 1993) |
| "Gastro-oesophageal reflux (GOR) has been implicated in such clinical phenomena as aspiration pneumonia, bronchospasm or wheezing, apnea, stridor, and hoarseness." | 5.29 | Gastro-oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride. ( Olafsdottir, E, 1995) |
| "Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter." | 5.28 | [Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride]. ( Carrasco Gandía, S; Lama Moré, R; Polanco Allue, I; Prieto Bozano, G, 1990) |
| " As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro-oesophageal reflux disease." | 5.10 | Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. ( Gardner, JD; Miner, PB; Robinson, M; Rodriguez-Stanley, S, 2002) |
| "To evaluate the efficiency of the 5-HT4 agonist and 5-HT3 antagonist mosapride, as compared with cisapride, on oesophageal acid reflux variables and oesophageal motor function in patients with chronic gastro-oesophageal reflux disease (GORD)." | 5.10 | The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. ( Cange, L; Finizia, C; Lundell, L; Ruth, M, 2003) |
| "To evaluate the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastro-oesophageal reflux." | 5.10 | The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease. ( Cange, L; Finizia, C; Lundell, L; Ruth, M, 2002) |
| "To investigate the effect of cisapride, a selective 5-hydroxytryptamine-4 receptor agonist, on the frequency of nocturnal transient lower oesophageal sphincter relaxations and oesophageal acid exposure in patients with gastro-oesophageal reflux disease." | 5.10 | Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. ( McCallum, R; Olyaee, M; Pehlivanov, N; Sarosiek, I; Whitman, R, 2002) |
| "Cisapride is a substituted piperidinyl benzamide indicated for the symptomatic treatment of patients with nocturnal heartburn due to gastro-oesophageal reflux disease (GERD)." | 5.09 | Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group. ( Castell, D; Jokubaitis, L; Littlejohn, T; Napolitano, J; Oleka, N; Orr, W; Silvers, D, 1999) |
| "To investigate the pharmacokinetics of enterally administered cisapride suspension in young infants being treated for gastro-oesophageal reflux disease." | 5.09 | Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. ( Charles, B; Donovan, T; Piotrovskij, V; Preechagoon, Y; Van Peer, A, 1999) |
| "This study was conducted to assess the efficacy of a novel 40-mg extended-release formulation of cisapride in reducing gastro-oesophageal reflux." | 5.09 | The efficacy of a 40-mg extended-release formulation of cisapride in the treatment of patients with gastro-oesophageal reflux. ( Arnold, R; Katschinski, M; Schirra, J, 2000) |
| "Enhanced gastric functioning and reduction in heartburn suggest that cisapride is efficacious in the treatment of older adults with symptomatic GERD, and that gastric dysrhythmias and postprandial fullness are resolved with cisapride treatment." | 5.09 | Gastric myoelectric activity in older adults treated with cisapride for gastro-oesophageal reflux disease. ( Chen, JD; McClanahan, J; Orr, WC; Sloan, S; Zhang, M, 2000) |
| "To evaluate whether prophylactic use of cisapride will reduce the incidence of feed intolerance and gastro-esophageal reflux, and improve gastric emptying in early neonatal period in preterm babies." | 5.09 | A double-blind placebo-controlled study on prophylactic use of cisapride on feed intolerance and gastric emptying in preterm neonates. ( Bal, CS; Deorari, AK; Paul, VK; Reddy, PS; Singh, M, 2000) |
| " Of these, 134 were on cisapride therapy for suspected gastroesophageal reflux and 118 were not on cisapride and served as controls." | 5.09 | Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. ( Benatar, A; Decraene, T; Feenstra, A; Vandenplas, Y, 2000) |
| "Gastrointestinal prokinetic agents, such as cisapride, are commonly used in pediatric practice to improve gastric emptying, to decrease emesis, to improve lower esophageal sphincter tone, and to improve irritability and feeding aversion associated with gastroesophageal reflux (GER)." | 5.09 | Cisapride decreases gastroesophageal reflux in preterm infants. ( Ariagno, RL; Baldwin, RB; Conrad, C; Kikkert, MA; Mirmiran, M, 2001) |
| "To study prospectively the effects of cisapride on ventricular repolarization, depolarization, and arrhythmia markers in neonates, we determined before and three days after starting cisapride (1 mg/kg/day): corrected QT interval (QTc) and QT dispersion (QTd) on standard ECGs, and duration of filtered QRS (fQRS) and of low amplitude (<40 microV) terminal signals (LAS40, ms) and root mean square of the last 40 ms (RMS40, microV) using high-gain signal-averaged ECG (SAECG)." | 5.09 | Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants. ( Belli, DC; Ferrazzini, G; Friedli, B; Zamora, SA, 2001) |
| "To access the efficacy of cisapride in facilitating acid clearance in patients with symptomatic gastro-oesophageal reflux disease." | 5.09 | The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease. ( Chen, CL; Orr, WC; Sloan, S, 2001) |
| "Cisapride and ranitidine improved the symptoms of diffuse epigastric pain, postprandial epigastric fullness, epigastric distension, belching, heartburn, regurgitation, and nausea when compared with baseline." | 5.08 | Cisapride compared with ranitidine in the treatment of functional dyspepsia. ( Carvalhinhos, A; Fidalgo, P; Freire, A; Matos, L, 1995) |
| "To evaluate the safety and efficacy of cisapride in patients with gastroesophageal reflux disease." | 5.08 | Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. ( Long, JF; Richter, JE, 1995) |
| "In patients with severe gastro-oesophageal reflux disease both cisapride and ranitidine demonstrably lower oesophageal acid exposure, but neither therapy predictably normalizes it." | 5.08 | A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. ( Kahrilas, PJ; Pouderoux, P, 1995) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 5.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| " The aim of this study was to look at duodenal reflux in the oesophagus together with motility characteristics in a group of patients with Barrett's oesophagus and compare them with a mild oesophagitis group and to assess the effect of cisapride on any abnormalities." | 5.08 | Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus. ( Bird, NC; Globe, J; Johnson, AG; Smythe, A; Troy, GP, 1997) |
| "We evaluated the efficacy and safety of a twice-daily dosage regimen of cisapride 20 mg in relieving the symptoms of mild-moderate gastroesophageal reflux disease (GERD) in patients with moderate intensity heartburn and no history of erosive esophagitis." | 5.08 | Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. ( Castell, DO; Clyde, C; Hasner, D; Lambert, R; Patterson, D; Sigmund, C; Zeldis, JB, 1998) |
| "Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children." | 5.08 | Proarrhythmia associated with cisapride in children. ( Berul, CI; Evangelista, JK; Fulton, DR; Hill, SL; Mobassaleh, M; Pizzi, AM, 1998) |
| "Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q." | 5.07 | Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. ( Anthopoulou, H; Arvanitakis, C; Giannoulis, E; Michailidis, D; Nikopoułos, A; Theoharidis, A; Tourkantonis, A; Vagios, I, 1993) |
| " We present single-subject trials of two pediatric patients done to assess the effect of cisapride on symptoms arising from gastroesophageal reflux." | 5.07 | The single-subject randomized trial. A useful clinical tool for assessing therapeutic efficacy in pediatric practice. ( Issenman, RM; Langer, JC; Winthrop, AL, 1993) |
| "The efficacy and tolerability of Cisapride effervescent granules for treatment of gastroesophageal reflux disease were compared to a metoclopramide-dimeticone combination." | 5.07 | [A new granular effervescent 10-mg formulation of cisapride in the treatment of gastroesophageal reflux]. ( Di Felice, F; Grossi, L; Marzio, L, 1993) |
| "We compared the efficacy of the prokinetic agent cisapride with that of Gaviscon (an alginate/alkaline compound) plus Carobel (carob seed flour) in the treatment of gastrooesophageal reflux (GOR)." | 5.07 | Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. ( Greally, P; Hampton, FJ; MacFadyen, UM; Simpson, H, 1992) |
| "Controlled studies showed that cisapride is effective in non-ulcer dyspepsia." | 5.07 | [Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms]. ( Fehr, HF, 1991) |
| "The effect of cisapride, a new gastrointestinal prokinetic drug, on oesophageal motility and acid reflux was studied in 14 children with gastro-oesophageal reflux disease, receiving either placebo or cisapride 0." | 5.06 | Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. ( Boccieri, A; Camerlingo, F; Capozzi, C; Cucchiara, S; De Stefano, M; Manzi, G; Paone, FM; Staiano, A, 1990) |
| "The influence of Cisapride on food-stimulated gastro-oesophageal reflux mechanisms was studied in a double-blind cross-over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro-oesophageal reflux and 12 with additional macroscopic oesophagitis." | 5.06 | Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study. ( Aksglade, K; Funch-Jensen, P; Gelineck, J; Thommesen, P, 1990) |
| "In a double-blind, randomized, comparative trial of the prokinetic drug cisapride and the H2-blocker cimetidine, mucosal healing and changes in symptoms of gastroesophageal reflux were evaluated in patients with erosive reflux esophagitis." | 5.06 | Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. ( Evreux, M; Filoche, B; Fournet, J; Fraitag, B; Galmiche, JP; Soule, JC; Vitaux, J; Zeitoun, P, 1990) |
| "We studied the effect of cisapride on oesophageal motor function and postprandial gastro-oesophageal reflux in a randomised, double blind, placebo controlled crossover study." | 5.06 | Effect of cisapride on postprandial gastro-oesophageal reflux. ( Dent, J; Downton, J; Holloway, RH; Mitchell, B, 1989) |
| "Since gastro-oesophageal reflux disease is due to disturbances of oesophageal motility, motor and pH measurements are an important means to test a new anti-reflux drug, cisapride." | 5.06 | Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. ( Li, Q; Wienbeck, M, 1989) |
| "In a double-blind, randomized study, the clinical effects of 5 mg and 10 mg of cisapride three times daily were compared with those of 10 mg of metoclopramide three times daily in 114 patients with symptoms of gastroesophageal reflux, mainly diurnal and nocturnal heartburn and regurgitation." | 5.06 | Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. ( Arabehety, JT; Fassler, S; Leitão, OR; Olarte, M; Serrano, C, 1988) |
| " Nine trials compared cisapride with placebo or no treatment, of which eight (262 participants) reported data on symptoms of gastro-oesophageal reflux." | 4.86 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Cash-Gibson, L; Gilbert, RE; Logan, S; Maclennan, S, 2010) |
| " Eight trials compared Cisapride with placebo, of which seven (236 participants) reported data on symptoms of gastro-oesophageal reflux, and one reported data on the QTc interval (49 patients)." | 4.82 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2003) |
| " Eight trials compared Cisapride with placebo, of which seven (236 participants) reported data on symptoms of gastro-oesophageal reflux, and one reported data on the QTc interval (49 patients)." | 4.81 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2002) |
| "This paper provides a comprehensive review of the current knowledge on cisapride in different clinical conditions in children: different manifestations of gastro-oesophageal reflux, such as (excessive) regurgitation, oesophagitis, chronic respiratory disease or uncontrolled asthma, cystic fibrosis, chronic dyspepsia, constipation and pseudo-obstruction, and as an aid to small bowel capsule-biopsy." | 4.80 | Clinical use of cisapride and its risk-benefit in paediatric patients. ( Vandenplas, Y, 1998) |
| "The prokinetic drug cisapride is widely used for treating gastro-oesophageal reflux in infants and children." | 4.80 | [Cisapride treatment for children with gastro-esophageal reflux]. ( Hoekstra, JH; Kneepkens, CM; Vandenplas, Y, 1999) |
| "The withdrawal of cisapride from the market will present challenges for physicians treating patients with nocturnal heartburn, gastroparesis, and dyspepsia." | 4.80 | Cisapride: limited access and alternatives. ( Richter, JE, 2000) |
| "The aim of the systematic review was to determine the effect of cisapride compared with placebo or other non-surgical therapies for the treatment of symptoms of gastro-oesophageal reflux in children." | 4.80 | Cisapride treatment for gastro-oesophageal reflux in children: a systematic review of randomized controlled trials. ( Augood, C; Gilbert, RE; Logan, S; MacLennan, S, 2000) |
| " These pharmacological differences have clinical relevance: metoclopramide and domperidon could not consistently prove efficacy in functional dyspepsia and GORD." | 4.79 | [Pharmacologic and clinical differentiation of prokinetic drugs]. ( Greving, I; May, B, 1996) |
| "The author discusses the role of prokinetic agents, such as bethanechol, metoclopramide, domperidone, and cisipride in the management of gastroesophageal reflux disease." | 4.78 | Gastric emptying in gastroesophageal reflux and the therapeutic role of prokinetic agents. ( McCallum, RW, 1990) |
| "Several studies have clearly demonstrated that omeprazole is highly efficacious in the management of patients with gastro-oesophageal reflux disease." | 4.77 | Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole? ( Klinkenberg-Knol, EC; Meuwissen, SG, 1989) |
| "Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal reflux symptoms." | 3.81 | Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide. ( Ashby, D; Croft, NM; Mt-Isa, S; Sutcliffe, A; Tomlin, S; Underwood, M; Williamson, P, 2015) |
| "Gastro-oesophageal reflux occurs when the pressure barrier of the lower oesophageal sphincter (LOS) fails due to a low basal pressure (less than or equal to 6 mm Hg), sphincteric relaxations or a noncompensated increase in intragastric pressure." | 3.76 | Pathophysiology and treatment of gastro-oesophageal reflux disease. ( Janssens, J; Vantrappen, G, 1989) |
| "Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves." | 3.76 | Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review. ( Richter, JE, 1989) |
| "We reviewed the medical records of all infants cisapride or metoclopramide in association with apnea." | 3.71 | Gastroesophageal reflux medications in the treatment of apnea in premature infants. ( Carlton, DP; Kimball, AL, 2001) |
| "A total of 211 infants were enrolled: 84 (17 born prematurely) undergoing cisapride therapy for at least 4 days for suspected gastroesophageal reflux and 127 controls (10 born prematurely), aged between 1 week and 13." | 3.71 | Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography. ( Benatar, A; Decraene, T; Feenstra, A; Vandenplas, Y, 2001) |
| "Apnea in the neonatal period frequently is associated with prematurity." | 3.70 | Gastric ulcer presenting as gastroesophageal reflux and apnea in a term neonate. ( Biskinis, EK; Naqvi, M; Skinner, S, 1998) |
| "The objective of this study was to compare the neonatal postoperative course and morbidity for patients with gastroschisis who received cisapride with those who did not receive cisapride." | 3.70 | Cisapride and caesarean section: their role in babies with gastroschisis. ( Duffy, B; Kumar, RK; Shi, EC, 1999) |
| "To evaluate the relationship between gastroesophageal reflux (GER) and obstructive sleep apnea (OSA) and the effect of combined therapy with cisapride and omeprazole." | 3.70 | [The relationship between obstructive sleep apnea and gastroesophageal reflux and the effect of antireflux therapy]. ( Huang, X; Ke, M; Wang, Z; Xiao, G, 1999) |
| "A 43-year-old woman with gastroesophageal reflux disease developed a dystonic-like reaction approximately 3 days after starting oral cisapride therapy." | 3.69 | Dystonic-like reaction following cisapride therapy. ( Abercrombie, SA; Bucci, KK; Haverstick, DE, 1995) |
| "A 2-month-old infant with gastroesophageal reflux was treated with cisapride." | 3.69 | Cisapride-induced long QT interval. ( Bryant, RM; Fenrich, AL; Grifka, RG; Lewin, MB, 1996) |
| "Cisapride is frequently used in the newborn and infant for treatment of gastroesophageal reflux." | 3.69 | [Long QT syndrome under cisapride in neonates and infants]. ( Aujard, Y; Bedu, A; Casasoprana, A; Cézard, JP; Denjoy, I; Faure, C; Lupoglazoff, JM, 1997) |
| "To evaluate the effectiveness of administration of oral cisapride in patients with gastro-esophageal reflux, we studied 25 children, aged 1 month-7 years (mean 16." | 3.68 | [Evaluation of the effectiveness of cisapride in the treatment of gastroesophageal reflux]. ( Balsamo, V; Carroccio, A; Cavataio, F; Iacono, G; Kazmierska, I; Lorello, D; Montalto, G; Soresi, M, 1992) |
| "Cisapride was used to treat gastro-oesophageal reflux in seven children with neurodevelopmental disorders and in 15 children who were neurologically normal." | 3.68 | The effects of cisapride on gastro-oesophageal reflux in children with and without neurological disorders. ( Brueton, MJ; Clarke, GS; Sandhu, BK, 1990) |
| "We studied the effects of positional treatment and cisapride (a new prokinetic agent) on the incidence and duration of gastroesophageal reflux in 22 infants (4-26 weeks old) in asleep, awake, fasted, and postcibal periods." | 3.67 | Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: treatment with cisapride. ( Aerts, T; Deneyer, M; Sacre, L; Vandenplas, Y; Verlinden, M, 1989) |
| "Cisapride was previously used in the same indication." | 2.74 | Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. ( Advani, N; Alatas, S; Firmansyah, A; Hegar, B; Vandenplas, Y, 2009) |
| " The remainder were concerned with medical intervention using a variety of dosing protocols." | 2.72 | Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma. ( Carson-Chahhoud, KV; Hnin, K; Kopsaftis, Z; Tin, KS; Yap, HS, 2021) |
| "Cisapride was related to a temporary relief of the symptoms in 10/12 children." | 2.69 | Effect of prokinetics in children with recurrent nocturnal retrosternal pain. ( de Pont, S; Hegar, B; Vandemaele, K; Vandenplas, Y, 1998) |
| " A randomized, double-blind, placebo-controlled, three-period incomplete crossover design was used with three dosing periods of 7 days." | 2.69 | The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. ( Samsom, M; Smout, AJ; Van Herwaarden, MA; Van Nispen, CH; Verlinden, M, 2000) |
| "Long-standing gastroesophageal reflux disease (GERD) is frequently associated with impaired esophageal body motility." | 2.69 | [Prokinetic medication after surgical therapy of reflux patients with disorders of esophageal peristalsis: a randomized clinical study]. ( Gadenstätter, M; Klocker, J; Weiss, H; Wetscher, GJ, 2000) |
| "Medical treatment of duodenogastroesophageal reflux in postgastrectomy patients has been disappointing." | 2.68 | Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. ( Richter, JE; Sears, R; Vaezi, MF, 1996) |
| "We hypothesised that gastro-oesophageal reflux (GOR) may exacerbate drooling by stimulation of the oesophago-salivary reflex." | 2.68 | Effect of antireflux medication on salivary drooling in children with cerebral palsy. ( Catto-Smith, AG; Heine, RG; Reddihough, DS, 1996) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 2.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Cisapride is a safe, well tolerated prokinetic agent that improves the esophageal clearance of refluxed gastric acid in children under the age of 2 years." | 2.68 | Cisapride in pediatric gastroesophageal reflux. ( Ferreira, C; Jones, AB; Lohoues, MJ; Machida, H; Roy, CC; Scott, RB; Smith, L, 1997) |
| "Cisapride has well-documented prokinetic effects and may be well suited for long-term therapy of GORD, but its effectiveness in purely symptomatic treatment is unknown." | 2.68 | The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. ( Carling, L; Hatlebakk, JG; Johnsson, F; Thøgersen, T; Vilien, M; Wetterhus, S, 1997) |
| "For diagnosis of gastroesophageal reflux, amongst other investigations, esophageal gammagraphy of swallowing, that detects alterations in the mobility of the oesophagus, secondary to a possible oesophagitis." | 2.67 | [Nocturnal spasmodic cough in the infant. Evolution after antireflux treatment]. ( Baltazar, MA; Botoy, J; Dordal, MT; Marques, L; Roca, I; Server, MT, 1994) |
| "Gastro-oesophageal reflux was very variable on both 24-h pH monitoring and acid reflux provocation test." | 2.67 | Cisapride in the treatment of gastro-oesophageal reflux disease. ( Atkinson, M; Evans, DF; Ledingham, SJ; Robertson, CS, 1993) |
| "Some patients with gastro-oesophageal reflux disease have delayed gastric emptying." | 2.67 | Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. ( Collins, PJ; Jamieson, GG; Maddern, GJ; Myers, JC, 1991) |
| "Cisapride or placebo was randomly added to positional treatment, prone-antiTrendelenburg position, which was applied to all infants." | 2.67 | Cisapride decreases prolonged episodes of reflux in infants. ( de Roy, C; Sacre, L; Vandenplas, Y, 1991) |
| "Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry." | 2.66 | Cisapride for gastro-oesophageal reflux and peptic oesophagitis. ( Auricchio, S; Boccieri, A; Capozzi, C; Cucchiara, S; Di Lorenzo, C; Staiano, A, 1987) |
| "Heartburn is a normal consequence of pregnancy." | 2.43 | Review article: the management of heartburn in pregnancy. ( Richter, JE, 2005) |
| "Gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) occur frequently during the first months of life." | 2.43 | The diagnosis and management of gastro-oesophageal reflux in infants. ( Hauser, B; Salvatore, S; Vandenplas, Y, 2005) |
| "Barrett's esophagus has to be regarded as a precancerous lesion, therefore surveillance strategy is required." | 2.43 | [Gastroesophageal reflux disease]. ( Gräter, H, 2005) |
| "Asthma and gastro-oesophageal reflux are both common medical conditions and often co-exist." | 2.42 | Gastro-oesophageal reflux treatment for asthma in adults and children. ( Coughlan, JL; Gibson, PG; Henry, RL, 2003) |
| "The choice of a medical therapy to treat gastroesophageal reflux disease (GERD) centers around several factors, including the efficacy and safety of the agent and the severity of the patient's symptoms and complications." | 2.42 | Profile and assessment of GERD pharmacotherapy. ( Maton, PN, 2003) |
| "Gastro-oesophageal reflux (GOR) disease is very common and, in the majority of infants, is physiological." | 2.41 | Pharmacotherapy of gastro-oesophageal reflux disease in children: focus on safety. ( Badriul, H; Hauser, B; Salvatore, S; Vandenplas, Y, 2002) |
| "Depending on the severity of the GERD manifestation, pharmacotherapy is often added." | 2.41 | Management of supraesophageal complications of gastroesophageal reflux disease in infants and children. ( Orenstein, SR, 2000) |
| "Asthma and gastro-oesophageal reflux are both common medical conditions and often co-exist." | 2.41 | Gastro-oesophageal reflux treatment for asthma in adults and children. ( Coughlan, JL; Gibson, PG; Henry, RL, 2000) |
| "Gastroesophageal reflux (GER) is a common problem which can manifest as vomiting, failure to thrive, recurrent pneumonias, asthma, sinusitus, or subglottic stenosis." | 2.41 | Medical management of gastroesophageal reflux. ( Brown, P, 2000) |
| "Gastro-oesophageal reflux (GOR) is an extremely common and usually self limiting condition in infants." | 2.41 | Cisapride treatment for gastro-oesophageal reflux in children. ( Augood, C; Gilbert, R; Logan, S; MacLennan, S, 2000) |
| "Gastro-oesophageal reflux is a frequent, aspecific phenomenon in infants and children." | 2.41 | Diagnosis and treatment of gastro-oesophageal reflux disease in infants and children. ( Hegar, B; Vandenplas, Y, 2000) |
| "Gastroesophageal reflux is a frequent, nonspecific phenomenon in infants and children." | 2.41 | Diagnosis and treatment of gastroesophageal reflux disease in infants and children. ( Vandenplas, Y, 2000) |
| "Cisapride has a better tolerability profile than a 'wait-and-see-if-improvement-comes-spontaneously' policy or the other therapeutic options available." | 2.41 | Efficacy and tolerability of cisapride in children. ( Arana, A; Benatar, A; Cools, F; Hauser, B; Hegar, B; Vandenplas, Y, 2001) |
| "The key factor in the pathogenesis of GERD is disordered function of the lower esophageal sphincter." | 2.40 | Prokinetic therapy in gastroesophageal reflux disease. ( Champion, MC, 1997) |
| "Gastroesophageal reflux disease results from excessive exposure of the oesophagus to acidic contents." | 2.40 | Acid pump inhibitors. The treatment of gastroesophageal reflux. ( Hetzel, D, 1998) |
| "Cisapride is a gastrointestinal prokinetic agent that is used worldwide in the treatment of gastrointestinal motility-related disorders in premature infants, full-term infants, and children." | 2.40 | The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. ( Belli, DC; Benatar, A; Cadranel, S; Cucchiara, S; Dupont, C; Gottrand, F; Hassall, E; Heymans, HS; Kearns, G; Kneepkens, CM; Koletzko, S; Milla, P; Polanco, I; Staiano, AM; Vandenplas, Y, 1999) |
| "Gastroesophageal reflux (GER) occurs in 2 distinct forms that differ in pathophysiology, clinical presentation, natural history, and therapy: mild GER (with no or minimal esophagitis) and classic, severe reflux (at risk for erosive esophagitis)." | 2.40 | Gastroesophageal reflux: practical management of a common, challenging disorder. ( Fass, R; Soll, AH, 1999) |
| "Severe gastroesophageal reflux disease is usually a chronic problem with periods of relapse, but effective medical and surgical therapies are available." | 2.39 | Severe gastroesophageal reflux disease. Medical and surgical options for long-term care. ( Marshall, JB, 1995) |
| "Cisapride was either equal to or superior to metoclopramide in relieving reflux symptoms." | 2.39 | Cisapride: a gastrointestinal prokinetic drug. ( Barone, JA; Bierman, RH; Colaizzi, JL; Jessen, LM, 1994) |
| "Gastro-oesophageal reflux disease is a primary motility disorder of the upper gastro-intestinal tract, with varying degrees of disturbed lower oesophageal sphincter function, disturbed peristalsis of the oesophageal body and delayed gastric emptying." | 2.39 | [Prokinetics in reflux disease. Action mechanisms and clinical effects]. ( Berstad, A; Hatlebakk, JG, 1994) |
| "Although gastroesophageal reflux disease is among the most common disorders seen by gastroenterologists, the wide variation in both its symptoms and severity has led to a lack of consensus about the most appropriate practical approach to treatment of patients with acute symptoms." | 2.39 | Individualized acute treatment strategies for gastroesophageal reflux disease. ( Reynolds, JC, 1995) |
| "Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for their symptoms." | 2.39 | Modern management of dyspepsia. ( Talley, NJ, 1996) |
| "The vast majority of patients with GERD have mild symptoms, no gross endoscopic evidence of esophagitis, and little risk of developing complications." | 2.39 | Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. ( Reynolds, JC, 1996) |
| " The appropriate use of prokinetic agents in these groups requires an understanding of the unique dosage considerations that may be necessary to ensure safe, effective therapy." | 2.39 | Use of prokinetic agents in special populations. ( Horn, JR, 1996) |
| " The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs." | 2.39 | Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. ( Berstad, A; Hatlebakk, JG, 1996) |
| "Gastro-oesophageal reflux is a common phenomenon in infants, and is an aspecific complaint." | 2.38 | The diagnosis and treatment of gastro-oesophageal reflux disease in infants and children. ( Vandenplas, Y, 1993) |
| "The cough was eliminated or markedly improved in 38 patients (86%) after 4 weeks and by 8 weeks in the remaining 6 patients." | 1.32 | Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. ( Kallay, MC; Poe, RH, 2003) |
| "We studied subjects with gastroesophageal reflux disease (apparent life-threatening events, apneas, bradycardias) before and 3 days after starting cisapride (0." | 1.32 | 24-hour electrocardiogram before and during cisapride treatment in neonates and infants. ( Belli, DC; Friedli, B; Jaeggi, E; Zamora, SA, 2004) |
| "A pathologically elevated gastroesophageal reflux was measured by means of 24-h pH-metry." | 1.32 | [Stenosing gastric laryngitis in infancy]. ( Hennig, A; Neumann, A; Schultz-Coulon, HJ, 2004) |
| "Cisapride treatment was assigned to the patients with pathologic monitoring results at a dose of 0." | 1.32 | Gastroesophageal reflux in children with cerebral palsy: efficacy of cisapride. ( Aydogdu, S; Bozkurt, M; Serdaroglu, G; Tekgul, H; Tutuncuoglu, S, 2004) |
| "Gastroesophageal reflux (GER) may aggravate chronic bronchopulmonary diseases." | 1.31 | Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. ( Brodzicki, J; Korzon, M; Trawińska-Bartnicka, M, 2002) |
| " In conclusion, cisapride has a positive influence on GOR parameters during caffeine treatment without impairing the oral bioavailability or therapeutic effect of caffeine." | 1.31 | Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine. ( Baisch, HJ; Heimann, G; Kentrup, H; Kusenbach, G; Skopnik, H, 2000) |
| "Gastroesophageal reflux disease (GERD) is one of the most frequently encountered illnesses in the Western Hemisphere." | 1.31 | Gastroesophageal reflux disease: pathophysiology and pharmacology overview. ( Dajani, EZ, 2000) |
| "Cisapride, which has recently been withdrawn by the Food and Drug Administration and is no longer an approved therapy, was commonly used for preterm infant care to improve the advance of enteral feedings and to reduce reflux and associated apnea." | 1.31 | Cisapride associated with QTc prolongation in very low birth weight preterm infants. ( Ariagno, R; Dubin, A; Kikkert, M; Mirmiran, M, 2001) |
| "Gastroesophageal reflux (GER) is very common in infants, especially in prematures and may be cause of gastrointestinal and cardiorespiratory symptoms." | 1.31 | [QTc interval in newborns with gastroesophageal reflux treated with cisapride and ranitidine]. ( Colli, A; Compagnoni, G; Introvini, P; Lista, G; Maestri, L; Massari, D; Menchini, M; Meroni, M; Porcelli, F, 2000) |
| "Gastroesophageal reflux (GER) is associated with a variety of laryngopharyngeal signs and symptoms." | 1.31 | Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux. ( Fuleihan, N; Hamdan, AL; Sharara, AI; Younes, A, 2001) |
| "Gastroesophageal reflux is a common, self-limited process in infants that usually resolves by six to 12 months of age." | 1.31 | Gastroesophageal reflux in infants and children. ( Jung, AD, 2001) |
| "Gastro-oesophageal reflux disease (GORD) has been described as a motility disorder of the upper gastrointestinal tract." | 1.31 | Prokinetics and reflux: a promise unfulfilled. ( de Caestecker, J, 2002) |
| " Linkage to cisapride was probable, promoted by high dosage and cisapride metabolism inhibition by ranitidine, but its plasma concentration was not measured." | 1.30 | [Syncope with long QT interval in a 39 day-old infant treated with cisapride]. ( Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997) |
| "Cisapride is a novel prokinetic agent that releases acetylcholine at the level of the myenteric plexus." | 1.30 | Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. ( Bityutskiy, LP; Goldin, GF; Marcinkiewicz, M; McCallum, RW; Sarosiek, J; Zbroch, T, 1997) |
| "In 21 GERD patients with RS, reflux was assessed by endoscopy, manometry, and pH monitoring." | 1.30 | Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery. ( Bammer, T; Glaser, K; Hinder, RA; Klingler, A; Klingler, P; Perdikis, G; Pointner, R; Schwab, G; Wetscher, GJ; Wieschemeyer, T, 1997) |
| "Only surgery improved regurgitation." | 1.30 | The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
| "Gastroesophageal reflux (GER) plays a causative role in the development of subglottic stenosis (SGS) in children." | 1.30 | Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis. ( Halstead, LA, 1999) |
| "Gastro-esophageal reflux disease is regarded as the single most common foregut disorder mainly in Western countries." | 1.30 | Surgical aspects of gastro-esophageal reflux disease--indication for surgery. An update. ( Bálint, A; Máté, M; Romics, L; Szabó, K, 1999) |
| "Eighty GERD patients with either dysphagia or respiratory symptoms were studied by means of a detailed symptom questionnaire, upper gastrointestinal endoscopy, esophageal manometry, 24-h esophageal pH monitoring and a barium esophagogram." | 1.30 | Respiratory symptoms and dysphagia in patients with gastroesophageal reflux disease: a comparison of medical and surgical therapy. ( Gadenstätter, M; Profanter, C; Schwab, GP; Wetscher, GJ; Wykypiel, H, 1999) |
| "Baclofen was used as a first treatment in patients without evidence of any gastro-oesophageal disease (n = 17), and was undertaken only after full treatment of such disease (n = 55) had failed to solve the hiccup problem (n = 20)." | 1.29 | Baclofen therapy for chronic hiccup. ( Bizec, JL; Cabane, J; Derenne, JP; Guelaud, C; Similowski, T; Whitelaw, WA, 1995) |
| "Cisapride is a recently available prokinetic agent that improves motility and emptying of the upper gastrointestinal tract in patients on long-term dialysis." | 1.29 | Cisapride. ( Hubbard, PM, 1994) |
| "We evaluated the prevalence of gastroesophageal reflux in 36 children, 22 (61." | 1.29 | Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. ( Fontana, R; Lami, CA; Novembre, E; Resti, M; Tucci, F; Vierucci, A, 1993) |
| "Cisapride was well tolerated and thus appears to be a useful option in the treatment of functional digestive disorders in a general practice setting." | 1.29 | Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices. ( Cardon, E; Jaecques, N; Lebrun, F; Meurant, JP; Rombouts, J; Spaepen, W; Verhaeghe, J, 1993) |
| "Respiratory complications of gastroesophageal reflux disease that have been reported include hoarseness, wheezing, bronchospasm, stridor, laryngitis, and chronic cough." | 1.29 | Gastroesophageal reflux-induced cough syncope. ( Puetz, TR; Vakil, N, 1995) |
| "Gastro-oesophageal reflux (GOR) has been implicated in such clinical phenomena as aspiration pneumonia, bronchospasm or wheezing, apnea, stridor, and hoarseness." | 1.29 | Gastro-oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride. ( Olafsdottir, E, 1995) |
| "Gastro-esophageal reflux (GER) in infants was studied using 24-hour esophageal pH monitoring." | 1.28 | [24-hour esophageal pH-metry in the evaluation of gastroesophageal reflux pathology]. ( Accorsini, M; Averbene, C; Caiulo, VA; Ceccarelli, M; Ughi, C, 1992) |
| "Weight gain was significant and recurrent cough and wheeze disappeared." | 1.28 | New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. ( Dab, I; Malfroot, A, 1991) |
| "Abnormal degrees of gastro-oesophageal reflux (GOR) were detected by 24 hour intraoesophageal pH measurement in 12 of 14 children (mean age 7." | 1.28 | Mechanisms of gastro-oesophageal reflux in cystic fibrosis. ( Andreotti, MR; Cucchiara, S; de Ritis, G; Ercolini, P; Minella, R; Oggero, V; Santamaria, F, 1991) |
| "Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter." | 1.28 | [Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride]. ( Carrasco Gandía, S; Lama Moré, R; Polanco Allue, I; Prieto Bozano, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (7.87) | 18.7374 |
| 1990's | 138 (54.33) | 18.2507 |
| 2000's | 89 (35.04) | 29.6817 |
| 2010's | 6 (2.36) | 24.3611 |
| 2020's | 1 (0.39) | 2.80 |
| Authors | Studies |
|---|---|
| Kopsaftis, Z | 1 |
| Yap, HS | 1 |
| Tin, KS | 1 |
| Hnin, K | 1 |
| Carson-Chahhoud, KV | 1 |
| Caraballo, L | 1 |
| Molina, G | 1 |
| Weitz, D | 1 |
| Piskulic, L | 1 |
| Avila, A | 1 |
| Marzi, M | 1 |
| Mt-Isa, S | 1 |
| Tomlin, S | 1 |
| Sutcliffe, A | 1 |
| Underwood, M | 1 |
| Williamson, P | 1 |
| Croft, NM | 1 |
| Ashby, D | 1 |
| Vakil, N | 2 |
| Nandurkar, S | 1 |
| Collins, KK | 1 |
| Sondheimer, JM | 1 |
| Hegar, B | 5 |
| Alatas, S | 1 |
| Advani, N | 1 |
| Firmansyah, A | 1 |
| Vandenplas, Y | 23 |
| Maclennan, S | 5 |
| Augood, C | 5 |
| Cash-Gibson, L | 1 |
| Logan, S | 5 |
| Gilbert, RE | 2 |
| Gottrand, F | 3 |
| Quigley, EM | 1 |
| Koivusalo, AI | 1 |
| Pakarinen, MP | 1 |
| Wikström, A | 1 |
| Rintala, RJ | 1 |
| Brodzicki, J | 1 |
| Trawińska-Bartnicka, M | 1 |
| Korzon, M | 1 |
| Gilbert, R | 3 |
| Kumar, Y | 4 |
| Sarvananthan, R | 4 |
| Gardner, JD | 1 |
| Rodriguez-Stanley, S | 1 |
| Robinson, M | 2 |
| Miner, PB | 1 |
| Dalby-Payne, JR | 1 |
| Morris, AM | 1 |
| Craig, JC | 1 |
| Smythe, A | 2 |
| Bird, NC | 2 |
| Troy, GP | 2 |
| Ackroyd, R | 1 |
| Johnson, AG | 2 |
| Poe, RH | 1 |
| Kallay, MC | 1 |
| Gibson, PG | 2 |
| Henry, RL | 2 |
| Coughlan, JL | 2 |
| Badriul, H | 1 |
| Salvatore, S | 2 |
| Hauser, B | 3 |
| Torringa, ML | 1 |
| van Roon, EN | 1 |
| de Vries, TW | 1 |
| Briganti, V | 1 |
| Oriolo, L | 1 |
| Calisti, A | 1 |
| Moayyedi, P | 1 |
| Delaney, B | 1 |
| Forman, D | 1 |
| Ruth, M | 2 |
| Finizia, C | 2 |
| Cange, L | 2 |
| Lundell, L | 2 |
| Khorana, M | 1 |
| Chankajorn, W | 1 |
| Kanjanapattanakul, W | 1 |
| Kirawittaya, T | 1 |
| Horpaopan, S | 1 |
| Chotigeat, U | 1 |
| Sangtawesin, W | 1 |
| Maton, PN | 1 |
| Zamora, SA | 2 |
| Belli, DC | 3 |
| Friedli, B | 2 |
| Jaeggi, E | 1 |
| Tamariz-Martel Moreno, A | 1 |
| Baño Rodrigo, A | 1 |
| Sánchez Bayle, M | 1 |
| Montero Luis, C | 1 |
| Acuña Quirós, MD | 1 |
| Cano Fernández, J | 1 |
| Hennig, A | 1 |
| Neumann, A | 1 |
| Schultz-Coulon, HJ | 1 |
| Dupont, C | 5 |
| Benhamou, PH | 2 |
| Bozkurt, M | 1 |
| Tutuncuoglu, S | 1 |
| Serdaroglu, G | 1 |
| Tekgul, H | 1 |
| Aydogdu, S | 1 |
| Richter, JE | 8 |
| Gräter, H | 1 |
| Carmagnola, S | 1 |
| Fraquelli, M | 1 |
| Cantù, P | 1 |
| Conte, D | 1 |
| Penagini, R | 1 |
| Bigard, MA | 1 |
| Keady, S | 1 |
| Lindahl, H | 1 |
| Rintala, R | 1 |
| Washabau, RJ | 1 |
| Hall, JA | 1 |
| Carvalhinhos, A | 1 |
| Fidalgo, P | 1 |
| Freire, A | 1 |
| Matos, L | 1 |
| Davies, AE | 1 |
| Sandhu, BK | 3 |
| Jia, B | 1 |
| Tytgat, GN | 3 |
| Blum, AL | 1 |
| Verlinden, M | 3 |
| Marshall, JB | 1 |
| Guelaud, C | 1 |
| Similowski, T | 1 |
| Bizec, JL | 1 |
| Cabane, J | 1 |
| Whitelaw, WA | 1 |
| Derenne, JP | 1 |
| Bucci, KK | 1 |
| Haverstick, DE | 1 |
| Abercrombie, SA | 1 |
| Long, JF | 1 |
| Hubbard, PM | 1 |
| Barone, JA | 1 |
| Jessen, LM | 1 |
| Colaizzi, JL | 1 |
| Bierman, RH | 1 |
| Ramirez, B | 1 |
| Dordal, MT | 1 |
| Baltazar, MA | 1 |
| Roca, I | 1 |
| Marques, L | 1 |
| Server, MT | 1 |
| Botoy, J | 1 |
| Arvanitakis, C | 1 |
| Nikopoułos, A | 1 |
| Theoharidis, A | 1 |
| Giannoulis, E | 1 |
| Vagios, I | 1 |
| Anthopoulou, H | 1 |
| Michailidis, D | 1 |
| Tourkantonis, A | 1 |
| Hatlebakk, JG | 3 |
| Berstad, A | 2 |
| Carella, G | 1 |
| Marra, L | 1 |
| Ashkenazi, A | 1 |
| Belli, D | 2 |
| Boige, N | 2 |
| Bouquet, J | 1 |
| Cadranel, S | 3 |
| Cezard, JP | 3 |
| Cucchiara, S | 8 |
| Geboes, K | 1 |
| Tucci, F | 1 |
| Resti, M | 1 |
| Fontana, R | 1 |
| Novembre, E | 1 |
| Lami, CA | 1 |
| Vierucci, A | 1 |
| Langer, JC | 1 |
| Winthrop, AL | 1 |
| Issenman, RM | 1 |
| Grossi, L | 1 |
| Di Felice, F | 1 |
| Marzio, L | 1 |
| Robertson, CS | 1 |
| Evans, DF | 1 |
| Ledingham, SJ | 1 |
| Atkinson, M | 1 |
| Verhaeghe, J | 1 |
| Jaecques, N | 1 |
| Rombouts, J | 1 |
| Spaepen, W | 1 |
| Cardon, E | 1 |
| Lebrun, F | 1 |
| Meurant, JP | 1 |
| Puetz, TR | 1 |
| Olafsdottir, E | 1 |
| Reynolds, JC | 3 |
| Talley, NJ | 1 |
| Lewin, MB | 1 |
| Bryant, RM | 1 |
| Fenrich, AL | 1 |
| Grifka, RG | 1 |
| Vaezi, MF | 1 |
| Sears, R | 1 |
| Campanozzi, A | 1 |
| Greco, L | 1 |
| Franco, MT | 1 |
| Emiliano, M | 1 |
| Alfieri, E | 1 |
| Calabrese, F | 1 |
| Numeroso, V | 1 |
| Sood, AK | 1 |
| Malhotra, RC | 1 |
| Sood, S | 1 |
| Pollmann, H | 1 |
| Zillessen, E | 1 |
| Pohl, J | 1 |
| Rosemeyer, D | 1 |
| Abucar, A | 1 |
| Armbrecht, U | 1 |
| Bornhofen, B | 1 |
| Herz, R | 1 |
| Pouderoux, P | 1 |
| Kahrilas, PJ | 1 |
| Faure, C | 3 |
| Hassall, E | 2 |
| Heymans, HS | 2 |
| Kneepkens, CM | 3 |
| Heine, RG | 1 |
| Catto-Smith, AG | 1 |
| Reddihough, DS | 1 |
| Horn, JR | 1 |
| Shulman, RJ | 2 |
| May, B | 1 |
| Greving, I | 1 |
| Mangal, N | 1 |
| Singh, J | 1 |
| Sharma, U | 1 |
| Patni, T | 1 |
| Bedu, A | 2 |
| Lupoglazoff, JM | 2 |
| Denjoy, I | 2 |
| Casasoprana, A | 2 |
| Aujard, Y | 2 |
| Hanson, R | 1 |
| Browne, G | 1 |
| Fasher, B | 1 |
| Mcaskill, M | 1 |
| Moroney, P | 1 |
| Hawker, R | 1 |
| Kazi, N | 1 |
| Mobarhan, S | 1 |
| Berkowitz, D | 1 |
| Naveh, Y | 1 |
| Berant, M | 1 |
| Corrado, G | 1 |
| D'Eufemia, P | 1 |
| Pacchiarotti, C | 1 |
| Cavaliere, M | 1 |
| Rea, P | 1 |
| Frandina, G | 1 |
| Giardini, O | 1 |
| Cardi, E | 1 |
| Halter, F | 1 |
| Staub, P | 1 |
| Hammer, B | 1 |
| Guyot, J | 1 |
| Miazza, BM | 1 |
| Valdes, L | 1 |
| Champel, V | 1 |
| Olivier, C | 1 |
| Jonville-Bera, AP | 1 |
| Autret, E | 1 |
| Goldin, GF | 1 |
| Marcinkiewicz, M | 1 |
| Zbroch, T | 1 |
| Bityutskiy, LP | 1 |
| McCallum, RW | 5 |
| Sarosiek, J | 1 |
| Galmiche, JP | 3 |
| Barthelemy, P | 1 |
| Hamelin, B | 1 |
| Champion, MC | 1 |
| Scott, RB | 1 |
| Ferreira, C | 1 |
| Smith, L | 1 |
| Jones, AB | 1 |
| Machida, H | 1 |
| Lohoues, MJ | 1 |
| Roy, CC | 1 |
| Johnsson, F | 1 |
| Vilien, M | 1 |
| Carling, L | 1 |
| Wetterhus, S | 1 |
| Thøgersen, T | 1 |
| Wetscher, GJ | 5 |
| Glaser, K | 3 |
| Hinder, RA | 3 |
| Perdikis, G | 1 |
| Klingler, P | 2 |
| Bammer, T | 1 |
| Wieschemeyer, T | 2 |
| Schwab, G | 1 |
| Klingler, A | 2 |
| Pointner, R | 1 |
| Sheptulin, AA | 1 |
| Muradov, NN | 1 |
| Bernardini, S | 1 |
| Semama, DS | 1 |
| Huet, F | 1 |
| Sgro, C | 1 |
| Gouyon, JB | 1 |
| Globe, J | 1 |
| Eggleston, A | 1 |
| Wigerinck, A | 1 |
| Huijghebaert, S | 1 |
| Dubois, D | 1 |
| Haycox, A | 1 |
| Heading, RC | 1 |
| Baldi, F | 1 |
| Holloway, RH | 2 |
| Janssens, J | 3 |
| Jian, R | 2 |
| Scarpignato, C | 1 |
| Sontag, SJ | 1 |
| Wienbeck, M | 2 |
| Castell, DO | 1 |
| Sigmund, C | 1 |
| Patterson, D | 1 |
| Lambert, R | 1 |
| Hasner, D | 1 |
| Clyde, C | 1 |
| Zeldis, JB | 1 |
| Shibata, Y | 1 |
| Nimura, Y | 1 |
| Toyoda, S | 1 |
| Yasui, A | 1 |
| Kawamura, T | 1 |
| Hill, SL | 1 |
| Evangelista, JK | 1 |
| Pizzi, AM | 1 |
| Mobassaleh, M | 1 |
| Fulton, DR | 1 |
| Berul, CI | 1 |
| Rothstein, SG | 1 |
| Hetzel, D | 1 |
| Field, SK | 1 |
| Sutherland, LR | 1 |
| Poynard, T | 1 |
| Vernisse, B | 1 |
| Agostini, H | 1 |
| Skinner, S | 1 |
| Naqvi, M | 1 |
| Biskinis, EK | 1 |
| Gadenstätter, M | 3 |
| Foucaud, P | 1 |
| Araujo, E | 1 |
| Bellaiche, M | 1 |
| Missonnier, S | 1 |
| de Pont, S | 1 |
| Vandemaele, K | 2 |
| Laheij, RJ | 1 |
| Jansen, JB | 1 |
| Severens, JL | 1 |
| Verbeek, AL | 1 |
| Cohen, RC | 1 |
| O'Loughlin, EV | 1 |
| Davidson, GP | 1 |
| Moore, DJ | 1 |
| Lawrence, DM | 1 |
| Coffin, B | 1 |
| Snape, WJ | 1 |
| Bosheva, M | 1 |
| Ivancheva, D | 1 |
| Genkova, N | 1 |
| Lutzkanova, Z | 1 |
| Klinkanova, M | 1 |
| Benatar, A | 5 |
| Feenstra, A | 3 |
| Decraene, T | 3 |
| McClure, RJ | 1 |
| Kristensen, JH | 1 |
| Grauaug, A | 1 |
| Mukhopadhyay, K | 1 |
| Narang, A | 1 |
| Kumar, P | 1 |
| Chakraborty, S | 1 |
| Mittal, BR | 1 |
| Gadenstaetter, M | 1 |
| Profanter, C | 2 |
| Halstead, LA | 1 |
| Kearns, G | 1 |
| Koletzko, S | 1 |
| Milla, P | 1 |
| Polanco, I | 1 |
| Staiano, AM | 1 |
| Chassany, O | 1 |
| Douet, MC | 1 |
| Ducrot, F | 1 |
| Kumar, RK | 1 |
| Shi, EC | 1 |
| Duffy, B | 1 |
| Castell, D | 1 |
| Silvers, D | 1 |
| Littlejohn, T | 1 |
| Orr, W | 1 |
| Napolitano, J | 1 |
| Oleka, N | 1 |
| Jokubaitis, L | 1 |
| Nurko, S | 2 |
| Hoekstra, JH | 1 |
| Heeringa, M | 1 |
| Pulles-Heintzberger, CF | 1 |
| van Puijenbroek, EP | 1 |
| Verduijn, MM | 1 |
| Preechagoon, Y | 1 |
| Charles, B | 1 |
| Piotrovskij, V | 1 |
| Donovan, T | 1 |
| Van Peer, A | 1 |
| Bálint, A | 1 |
| Máté, M | 1 |
| Szabó, K | 1 |
| Romics, L | 1 |
| Katschinski, M | 1 |
| Schirra, J | 1 |
| Arnold, R | 1 |
| Markiewicz, M | 1 |
| Vanden Plas, Y | 1 |
| Lee, WS | 1 |
| Beattie, RM | 1 |
| Meadows, N | 1 |
| Walker-Smith, JA | 1 |
| Wykypiel, H | 1 |
| Schwab, GP | 1 |
| Khoshoo, V | 1 |
| Edell, D | 1 |
| Clarke, R | 1 |
| Kentrup, H | 1 |
| Baisch, HJ | 1 |
| Kusenbach, G | 1 |
| Heimann, G | 1 |
| Skopnik, H | 1 |
| Soll, AH | 1 |
| Fass, R | 1 |
| Dinler, G | 1 |
| Ozen, H | 1 |
| Koçak, N | 1 |
| Yüce, A | 1 |
| Gürakan, F | 1 |
| Orenstein, SR | 1 |
| Orr, WC | 2 |
| Zhang, M | 1 |
| McClanahan, J | 1 |
| Sloan, S | 2 |
| Chen, JD | 1 |
| Craig, JS | 1 |
| McClure, BG | 1 |
| Tubman, TR | 1 |
| SoRelle, R | 1 |
| Bourke, B | 2 |
| Drumm, B | 2 |
| Van Herwaarden, MA | 1 |
| Samsom, M | 1 |
| Van Nispen, CH | 1 |
| Smout, AJ | 1 |
| Dajani, EZ | 1 |
| Brown, P | 1 |
| Davies, MW | 1 |
| Reddy, PS | 1 |
| Deorari, AK | 1 |
| Bal, CS | 1 |
| Paul, VK | 1 |
| Singh, M | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Flook, N | 1 |
| Chiba, N | 1 |
| Armstrong, D | 1 |
| Barkun, A | 1 |
| Bradette, M | 1 |
| Thomson, A | 1 |
| Bursey, F | 1 |
| Blackshaw, P | 1 |
| Frail, D | 1 |
| Sinclair, P | 1 |
| Arana, A | 2 |
| Ramírez-Mayans, J | 1 |
| Garrido-García, LM | 1 |
| Huerta-Tecanhuey, A | 1 |
| Gutierrez-Castrellón, P | 1 |
| Cervantes-Bustamante, R | 1 |
| Mata-Rivera, N | 1 |
| Zárate-Mondragón, F | 1 |
| Klocker, J | 1 |
| Weiss, H | 1 |
| Kubler, PA | 1 |
| Pillans, PI | 1 |
| McKay, JR | 1 |
| Kimball, AL | 1 |
| Carlton, DP | 1 |
| Ariagno, RL | 1 |
| Kikkert, MA | 1 |
| Mirmiran, M | 2 |
| Conrad, C | 1 |
| Baldwin, RB | 1 |
| Dubin, A | 1 |
| Kikkert, M | 1 |
| Ariagno, R | 1 |
| Levy, J | 1 |
| Hayes, C | 1 |
| Kern, J | 1 |
| Harris, J | 1 |
| Flores, A | 1 |
| Hyams, J | 1 |
| Murray, R | 1 |
| Tolia, V | 1 |
| Lista, G | 1 |
| Maestri, L | 1 |
| Meroni, M | 1 |
| Massari, D | 1 |
| Colli, A | 1 |
| Porcelli, F | 1 |
| Menchini, M | 1 |
| Introvini, P | 1 |
| Compagnoni, G | 1 |
| Ferrazzini, G | 1 |
| Lee, P | 1 |
| Rudolph, C | 1 |
| van Rensburg, CJ | 1 |
| Bardhan, KD | 1 |
| García Aroca, J | 1 |
| Alonso Calderón, JL | 1 |
| García Redondo, C | 1 |
| Rollán Villamarín, V | 1 |
| Chen, CL | 1 |
| Cools, F | 1 |
| Kemppinen, H | 1 |
| Korppi, M | 1 |
| Hamdan, AL | 1 |
| Sharara, AI | 1 |
| Younes, A | 1 |
| Fuleihan, N | 1 |
| Rana, S | 1 |
| Sharma, B | 1 |
| Jung, AD | 1 |
| de Caestecker, J | 1 |
| Xiao, G | 1 |
| Wang, Z | 1 |
| Ke, M | 1 |
| Huang, X | 1 |
| Chattopadhyay, A | 1 |
| Singh, S | 1 |
| Sood, A | 1 |
| Wanchu, A | 1 |
| Bambery, P | 1 |
| Glessner, MR | 1 |
| Heller, DA | 1 |
| Pehlivanov, N | 1 |
| Sarosiek, I | 1 |
| Whitman, R | 1 |
| Olyaee, M | 1 |
| McCallum, R | 1 |
| Shaoul, R | 1 |
| Shahory, R | 1 |
| Tamir, A | 1 |
| Jaffe, M | 1 |
| Iacono, G | 3 |
| Carroccio, A | 3 |
| Montalto, G | 3 |
| Cavataio, F | 3 |
| Lorello, D | 2 |
| Soresi, M | 1 |
| Kazmierska, I | 2 |
| Balsamo, V | 2 |
| Dent, J | 2 |
| Li Voti, G | 1 |
| Tulone, V | 1 |
| Acierno, C | 1 |
| Notarbartolo, A | 1 |
| Greally, P | 2 |
| Hampton, FJ | 2 |
| MacFadyen, UM | 2 |
| Simpson, H | 2 |
| Goldberg, J | 1 |
| Accorsini, M | 1 |
| Averbene, C | 1 |
| Caiulo, VA | 1 |
| Ughi, C | 1 |
| Ceccarelli, M | 1 |
| Menezes, O | 1 |
| Malfroot, A | 2 |
| Dab, I | 2 |
| Chéron, G | 1 |
| Bernard, F | 1 |
| Sallenave, JR | 1 |
| Jenkins, HR | 1 |
| Verrier-Jones, K | 1 |
| Santamaria, F | 1 |
| Andreotti, MR | 1 |
| Minella, R | 1 |
| Ercolini, P | 1 |
| Oggero, V | 1 |
| de Ritis, G | 1 |
| Maddern, GJ | 1 |
| Jamieson, GG | 1 |
| Myers, JC | 1 |
| Collins, PJ | 1 |
| de Roy, C | 1 |
| Sacre, L | 2 |
| Fehr, HF | 1 |
| Newell, SJ | 1 |
| Brueton, MJ | 1 |
| Clarke, GS | 1 |
| Staiano, A | 2 |
| Boccieri, A | 2 |
| De Stefano, M | 1 |
| Capozzi, C | 2 |
| Manzi, G | 1 |
| Camerlingo, F | 1 |
| Paone, FM | 1 |
| Gelineck, J | 1 |
| Aksglade, K | 1 |
| Funch-Jensen, P | 1 |
| Thommesen, P | 1 |
| Carrasco Gandía, S | 1 |
| Lama Moré, R | 1 |
| Prieto Bozano, G | 1 |
| Polanco Allue, I | 1 |
| Janssens, G | 1 |
| Melis, K | 1 |
| Vaerenberg, M | 1 |
| Sekiguchi, T | 1 |
| Nishioka, Ta | 1 |
| Kawamura, O | 1 |
| Kikuchi, K | 1 |
| Horikoshi, T | 1 |
| Machida, M | 1 |
| Matsuzaki, T | 1 |
| Kusano, M | 1 |
| Sugiyama, T | 1 |
| Tsuchinuki, M | 1 |
| Fraitag, B | 2 |
| Filoche, B | 1 |
| Evreux, M | 1 |
| Vitaux, J | 1 |
| Zeitoun, P | 1 |
| Fournet, J | 1 |
| Soule, JC | 1 |
| Demling, L | 2 |
| Vantrappen, G | 2 |
| Meuwissen, SG | 1 |
| Klinkenberg-Knol, EC | 1 |
| Cloarec, D | 1 |
| Downton, J | 1 |
| Mitchell, B | 1 |
| Reyntjens, A | 1 |
| Li, Q | 1 |
| Saye, Z | 1 |
| Forget, PP | 1 |
| Deneyer, M | 1 |
| Aerts, T | 1 |
| Nio, CY | 1 |
| Arabehety, JT | 1 |
| Leitão, OR | 1 |
| Fassler, S | 1 |
| Olarte, M | 1 |
| Serrano, C | 1 |
| Ricci, DA | 1 |
| Ceccatelli, P | 1 |
| Di Lorenzo, C | 1 |
| Auricchio, S | 1 |
| Collins, BJ | 1 |
| Spence, RA | 1 |
| Ferguson, R | 1 |
| Laird, J | 1 |
| Love, AH | 1 |
| Rode, H | 1 |
| Stunden, RJ | 1 |
| Millar, AJ | 1 |
| Cywes, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Efficacy of Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy : A Randomized Double-Blind Controlled Trial[NCT02470117] | Phase 4 | 100 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study[NCT02706938] | 65 participants (Actual) | Interventional | 2016-04-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Secondary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | 6.5992 |
| Control | -0.3139 |
Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Primary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | -1.2397 |
| Control | 0.0869 |
Percentage of patients who preferred head of bed elevation after trial ending (NCT02706938)
Timeframe: Secondary outcome will be assessed 14 weeks after starting the trial
| Intervention | percent of participants (Number) |
|---|---|
| All Participants | 63.158 |
76 reviews available for cisapride and Gastroesophageal Reflux
| Article | Year |
|---|---|
Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma.
Topics: Acute Disease; Adult; Anti-Asthmatic Agents; Asthma; Child; Cisapride; Disease Progression; Forced E | 2021 |
[Proarrhythmic effects of domperidone in infants: a systematic review].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Cisapride; Contraindications; Cytochrome P-450 CYP3A; Dom | 2014 |
New pharmacological agents for the treatment of gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Benzamides; Cisapride; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Huma | 2008 |
Cisapride treatment for gastro-oesophageal reflux in children.
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; Infa | 2010 |
[Prokinetics in childhood].
Topics: Adolescent; Anti-Ulcer Agents; Antiemetics; Bethanechol; Child; Child, Preschool; Cisapride; Cross-S | 2010 |
Cisapride: what can we learn from the rise and fall of a prokinetic?
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Diseases; Gastrointestinal Motility; Gastropare | 2011 |
Cisapride treatment for gastro-oesophageal reflux in children.
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; Infa | 2002 |
Gastro-oesophageal reflux in children.
Topics: Alginates; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Fundoplication; Gastroesophageal | 2002 |
Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children.
Topics: Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Randomized Controlled Tr | 2003 |
Gastro-oesophageal reflux in children.
Topics: Alginates; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Fundoplication; Gastroesophageal | 2002 |
Gastro-oesophageal reflux treatment for asthma in adults and children.
Topics: Adult; Asthma; Child; Cisapride; Gastroesophageal Reflux; Histamine Antagonists; Humans; Proton Pump | 2003 |
Pharmacotherapy of gastro-oesophageal reflux disease in children: focus on safety.
Topics: Anti-Ulcer Agents; Child; Cisapride; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infa | 2002 |
Gastro-oesophageal reflux disease.
Topics: Antacids; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Histamine H2 Antagonists; Hum | 2003 |
Cisapride treatment for gastro-oesophageal reflux in children.
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; Infa | 2003 |
Profile and assessment of GERD pharmacotherapy.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Controlled Clinical Trials as Topic; Domperidone; Esophag | 2003 |
Gastro-oesophageal reflux in children.
Topics: Alginates; Child; Child, Preschool; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Glu | 2003 |
Gastro-oesophageal reflux in children.
Topics: Alginates; Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Glucuronic Acid; Hexu | 2004 |
Review article: the management of heartburn in pregnancy.
Topics: Antacids; Anti-Ulcer Agents; Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Motility; | 2005 |
The diagnosis and management of gastro-oesophageal reflux in infants.
Topics: Antacids; Cisapride; Domperidone; Erythromycin; Gastric Mucosa; Gastroesophageal Reflux; Histamine H | 2005 |
[Gastroesophageal reflux disease].
Topics: Aged; Antacids; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Cisapride; Diagnosis, Differential; En | 2005 |
[Therapeutic innovations in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Catheter Ablation; Cisapride; End | 2007 |
Update on drugs for gastro-oesophageal reflux disease.
Topics: Adolescent; Antacids; Child; Child, Preschool; Cisapride; Contraindications; Domperidone; Erythromyc | 2007 |
Cisapride.
Topics: Animals; Cisapride; Esophagus; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Motility; | 1995 |
Prokinetic therapy for gastroesophageal reflux disease.
Topics: Bethanechol; Cisapride; Domperidone; Erythromycin; Gastroesophageal Reflux; Humans; Metoclopramide; | 1995 |
Severe gastroesophageal reflux disease. Medical and surgical options for long-term care.
Topics: Antacids; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophageal Diseases; Esophagogast | 1995 |
Cisapride: a gastrointestinal prokinetic drug.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Constipation; Double-Blind Method; Dy | 1994 |
Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease.
Topics: Adult; Benzamides; Bethanechol; Bethanechol Compounds; Child; Cisapride; Erythromycin; Gastroesophag | 1993 |
[Prokinetics in reflux disease. Action mechanisms and clinical effects].
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Motility; Humans; Piperidines; Serotonin Antago | 1994 |
The diagnosis and treatment of gastro-oesophageal reflux disease in infants and children.
Topics: Anti-Ulcer Agents; Child, Preschool; Cisapride; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Ga | 1993 |
A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN
Topics: Child; Child Nutritional Physiological Phenomena; Cisapride; Esophagitis; Esophagoscopy; Esophagus; | 1993 |
Individualized acute treatment strategies for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Histamine H2 Antagon | 1995 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; C | 1996 |
Current concepts and issues in the management of regurgitation of infants: a reappraisal. Management guidelines from a working party.
Topics: Anti-Ulcer Agents; Antiemetics; Cisapride; Gastroesophageal Reflux; Humans; Infant; Infant Food; Met | 1996 |
Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Cisapride; Drug Interactions; Drug Therapy, Combination; Esophagitis, Pepti | 1996 |
Use of prokinetic agents in special populations.
Topics: Age Factors; Cisapride; Drug Interactions; Gastroesophageal Reflux; Gastrointestinal Agents; Gastroi | 1996 |
[Pharmacologic and clinical differentiation of prokinetic drugs].
Topics: Adult; Antiemetics; Child; Cisapride; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; D | 1996 |
Cisapride.
Topics: Anti-Ulcer Agents; Child, Preschool; Cisapride; Gastroesophageal Reflux; Humans; Infant; Infant, New | 1995 |
Enteral feeding associated gastroesophageal reflux and aspiration pneumonia: a review.
Topics: Bethanechol; Cisapride; Enteral Nutrition; Gastroesophageal Reflux; Humans; Nutrition Disorders; Par | 1996 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidon | 1996 |
Prokinetic therapy in gastroesophageal reflux disease.
Topics: Cisapride; Domperidone; Esophagus; Gastroesophageal Reflux; Gastrointestinal Agents; Histamine H2 An | 1997 |
[A new prokinetic drug cisapride: pharmacological properties and clinical potential].
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Piperidines | 1997 |
Managing childhood gastro-oesophageal reflux.
Topics: Alginates; Aluminum Hydroxide; Antacids; Child; Cisapride; Drug Combinations; Gastroesophageal Reflu | 1997 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 1998 |
Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature.
Topics: Antacids; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Cimetidine; Circadian Rhythm; Cisapride; | 1998 |
[Gastroesophageal reflux in infants: excessive medication?].
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Humans; Infant; Sudden Infant Death | 1998 |
Clinical use of cisapride and its risk-benefit in paediatric patients.
Topics: Child; Child, Preschool; Cisapride; Constipation; Cystic Fibrosis; Drug Interactions; Dyspepsia; Fec | 1998 |
Cisapride doesn't work? Don't go breakin' my heart!
Topics: Cisapride; Clinical Trials as Topic; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydro | 1999 |
[Medical treatment of gastroesophageal reflux by prokinetic drugs].
Topics: Anti-Ulcer Agents; Benzamides; Cisapride; Dopamine Antagonists; Gastroesophageal Reflux; Humans; Met | 1999 |
[Gastroesophageal reflux in adults: diagnosis and treatment. Conclusions of Consensus Conference: long text. Organized by the French National Society of Gastroenterology and Belgian Royal Society of Gastroenterology/Flemish Society of Gastroenterology. Fr
Topics: Adult; Age Factors; Antacids; Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Diagnosis, Dif | 1999 |
[Gastroesophageal reflux in adults: diagnosis and treatment. Conclusions of Consensus Conference: short text. Organized by the French National Society of Gastroenterology and Belgian Royal Society of Gastroenterology/Flemish Society of Gastroenterology. F
Topics: Adult; Age Factors; Antacids; Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Diagnosis, Dif | 1999 |
The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Topics: Arrhythmias, Cardiac; Cisapride; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Intera | 1999 |
[Cisapride treatment for children with gastro-esophageal reflux].
Topics: Child; Cisapride; Drug Approval; Drug Interactions; Gastroesophageal Reflux; Gastrointestinal Agents | 1999 |
Gastroesophageal reflux: practical management of a common, challenging disorder.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Cisapride; Endoscopy, Gastrointestinal; Gastrins; Gastroesopha | 1999 |
Management of supraesophageal complications of gastroesophageal reflux disease in infants and children.
Topics: Bethanechol; Child; Child, Preschool; Cimetidine; Cisapride; Fundoplication; Gastroesophageal Reflux | 2000 |
Gastro-oesophageal reflux treatment for asthma in adults and children.
Topics: Adult; Asthma; Child; Cisapride; Gastroesophageal Reflux; Histamine Antagonists; Humans; Proton Pump | 2000 |
Medical management of gastroesophageal reflux.
Topics: Anti-Ulcer Agents; Child; Cisapride; Combined Modality Therapy; Gastroesophageal Reflux; Histamine H | 2000 |
Cisapride: limited access and alternatives.
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Dyspepsia; Female; Ga | 2000 |
Cisapride treatment for gastro-oesophageal reflux in children.
Topics: Alginates; Aluminum Hydroxide; Anti-Ulcer Agents; Cisapride; Drug Combinations; Gastroesophageal Ref | 2000 |
Diagnosis and treatment of gastro-oesophageal reflux disease in infants and children.
Topics: Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2000 |
Diagnosis and treatment of gastroesophageal reflux disease in infants and children.
Topics: Child; Cisapride; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2000 |
Cisapride treatment for gastro-oesophageal reflux in children: a systematic review of randomized controlled trials.
Topics: Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Randomized Controlled Tr | 2000 |
Gastroesophageal reflux in infants and children.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; Esophageal Diseases; Fundoplication; Gastroes | 2001 |
Efficacy and tolerability of cisapride in children.
Topics: Child; Child, Preschool; Cisapride; Clinical Trials as Topic; Drug Tolerance; Endpoint Determination | 2001 |
Gastroesophageal reflux: diagnosis and management.
Topics: Alginates; Antacids; Barium; Bethanechol Compounds; Cisapride; Endoscopy, Gastrointestinal; Gastric | 1992 |
Heartburn--lifting the veil of mythology.
Topics: Antacids; Cisapride; Esophagus; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans | 1992 |
[Disorders of gastric emptying].
Topics: Cisapride; Diabetes Complications; Domperidone; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux | 1992 |
Gastric emptying in gastroesophageal reflux and the therapeutic role of prokinetic agents.
Topics: Bethanechol; Bethanechol Compounds; Cisapride; Domperidone; Esophagogastric Junction; Gastric Emptyi | 1990 |
Cisapride--more selective than metoclopramide.
Topics: Cisapride; Dyspepsia; Gastroesophageal Reflux; Gastrointestinal Motility; Humans; Metoclopramide; Pi | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole?
Topics: Cisapride; Drug Administration Schedule; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1989 |
[Cisapride: pharmacology, current therapeutic results and future prospects].
Topics: Cisapride; Constipation; Dyspepsia; Esophagitis; Esophagus; Forecasting; Gastric Emptying; Gastroeso | 1989 |
Prokinetic agents: a key in the future of gastroenterology.
Topics: Biomechanical Phenomena; Cisapride; Domperidone; Forecasting; Gastroenterology; Gastroesophageal Ref | 1989 |
Rationale for the development of a novel gastrointestinal prokinetic, cisapride.
Topics: Cisapride; Gastric Emptying; Gastroesophageal Reflux; Humans; Myenteric Plexus; Piperidines; Seroton | 1989 |
Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review.
Topics: Adult; Child; Cisapride; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Me | 1989 |
The medical therapy of reflux oesophagitis.
Topics: Antacids; Bethanechol; Bethanechol Compounds; Cimetidine; Cisapride; Domperidone; Esophagitis, Pepti | 1987 |
Diagnosis and treatment of delayed gastric emptying.
Topics: Anemia, Pernicious; Anorexia Nervosa; Cisapride; Connective Tissue Diseases; Diabetes Complications; | 1988 |
64 trials available for cisapride and Gastroesophageal Reflux
| Article | Year |
|---|---|
Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study.
Topics: Antiemetics; Cardiovascular System; Cisapride; Domperidone; Electrocardiography; Esophageal pH Monit | 2009 |
Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
Topics: Adult; Cisapride; Cross-Over Studies; Female; Gastric Acid; Gastric Acidity Determination; Gastric E | 2002 |
Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barrett's oesophagus?
Topics: Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Cisapride; Double-Blind Method; Drug Therapy, Com | 2003 |
The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease.
Topics: Adult; Aged; Benzamides; Cisapride; Cross-Over Studies; Double-Blind Method; Drug Administration Sch | 2003 |
Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Endoscopy, Gastrointestinal; Esophagus; Female; Gastric | 2006 |
Cisapride compared with ranitidine in the treatment of functional dyspepsia.
Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Eructation; Female; F | 1995 |
Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease.
Topics: Cisapride; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Piperidines; Prognosis; Prospective | 1995 |
Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Drug Administration | 1995 |
[Nocturnal spasmodic cough in the infant. Evolution after antireflux treatment].
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cough; Domperidone; Female; Gastroesophageal Reflux; | 1994 |
Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Female; Gastric Acid; Gastroesophageal Ref | 1993 |
The single-subject randomized trial. A useful clinical tool for assessing therapeutic efficacy in pediatric practice.
Topics: Adult; Child; Child, Preschool; Cisapride; Gagging; Gastroesophageal Reflux; Humans; Infant; Male; P | 1993 |
[A new granular effervescent 10-mg formulation of cisapride in the treatment of gastroesophageal reflux].
Topics: Adult; Aged; Cisapride; Double-Blind Method; Drug Combinations; Drug Tolerance; Female; Gastroesopha | 1993 |
Cisapride in the treatment of gastro-oesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Endoscopy, Digestive System; Esophagitis, Peptic; Femal | 1993 |
Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux.
Topics: Anti-Ulcer Agents; Bilirubin; Cisapride; Cross-Over Studies; Double-Blind Method; Duodenogastric Ref | 1996 |
[Effect of elevated head position in bed in therapy of gastroesophageal reflux].
Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Femal | 1996 |
A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Esophagitis, Peptic; Female; Gastric Acid; Gastric Acidity Dete | 1995 |
Effect of antireflux medication on salivary drooling in children with cerebral palsy.
Topics: Adolescent; Cerebral Palsy; Child; Child, Preschool; Cisapride; Esophagus; Female; Gastroesophageal | 1996 |
Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Domperidone; Double-Blind Method; Dyspepsia; Female; Follow-Up | 1997 |
Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Ga | 1997 |
Cisapride in pediatric gastroesophageal reflux.
Topics: Biopsy; Cisapride; Double-Blind Method; Esophagus; Gastroesophageal Reflux; Gastrointestinal Agents; | 1997 |
The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
Topics: Abdominal Pain; Cisapride; Constipation; Diarrhea; Drug Administration Schedule; Endoscopy; Esophagi | 1997 |
Effects of cisapride on QTc interval in neonates.
Topics: Cisapride; Electrocardiography; Gastroesophageal Reflux; Gestational Age; Humans; Infant, Newborn; I | 1997 |
Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus.
Topics: Adult; Aged; Barrett Esophagus; Bile Acids and Salts; Cisapride; Duodenogastric Reflux; Electrodes; | 1997 |
Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
Topics: Adolescent; Adult; Aged; Antacids; Cisapride; Eructation; Female; Gastroesophageal Reflux; Gastroint | 1998 |
Proarrhythmia associated with cisapride in children.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastro | 1998 |
Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.
Topics: Adult; Alginates; Anti-Ulcer Agents; Cisapride; Female; France; Gastroesophageal Reflux; Glucuronic | 1998 |
Cisapride enhances the effect of partial posterior fundoplication on esophageal peristalsis in GERD patients with poor esophageal contractility.
Topics: Adult; Aged; Cisapride; Esophagus; Female; Fundoplication; Gastroesophageal Reflux; Gastrointestinal | 1998 |
Effect of prokinetics in children with recurrent nocturnal retrosternal pain.
Topics: Child; Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Con | 1998 |
Cisapride in the control of symptoms in infants with gastroesophageal reflux: A randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Australia; Chi-Square Distribution; Cisapride; Double-Blind Method; Esophagus; | 1999 |
Cisapride and proarrhythmia in childhood.
Topics: Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; In | 1999 |
Randomised controlled trial of cisapride in preterm infants.
Topics: Cisapride; Contraindications; Cross-Over Studies; Double-Blind Method; Gastric Emptying; Gastroesoph | 1999 |
Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal | 1999 |
Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease.
Topics: Analysis of Variance; Bayes Theorem; Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Ag | 1999 |
The efficacy of a 40-mg extended-release formulation of cisapride in the treatment of patients with gastro-oesophageal reflux.
Topics: Adolescent; Adult; Aged; Cisapride; Delayed-Action Preparations; Double-Blind Method; Esophagus; Fem | 2000 |
Gastric myoelectric activity in older adults treated with cisapride for gastro-oesophageal reflux disease.
Topics: Aged; Aged, 80 and over; Cisapride; Female; Gastric Acid; Gastroesophageal Reflux; Heartburn; Humans | 2000 |
The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients.
Topics: Adult; Cisapride; Cross-Over Studies; Double-Blind Method; Erythromycin; Esophagus; Female; Gastroes | 2000 |
A double-blind placebo-controlled study on prophylactic use of cisapride on feed intolerance and gastric emptying in preterm neonates.
Topics: Cisapride; Double-Blind Method; Food Hypersensitivity; Gastric Emptying; Gastroesophageal Reflux; Ga | 2000 |
Cisapride and QTc interval in children.
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Cisapride; Electrocardiography, Ambulator | 2000 |
Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography.
Topics: Arrhythmias, Cardiac; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agen | 2000 |
[Prokinetic medication after surgical therapy of reflux patients with disorders of esophageal peristalsis: a randomized clinical study].
Topics: Adult; Aged; Cisapride; Esophageal Motility Disorders; Female; Follow-Up Studies; Fundoplication; Ga | 2000 |
Cisapride decreases gastroesophageal reflux in preterm infants.
Topics: Cisapride; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gast | 2001 |
Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study.
Topics: Arrhythmias, Cardiac; Child, Preschool; Cisapride; Electrocardiography; Female; Gastroesophageal Ref | 2001 |
Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants.
Topics: Arrhythmias, Cardiac; Biomarkers; Cisapride; Electrocardiography; Electrophysiology; Gastroesophagea | 2001 |
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cisapride; Double-Blind Method; Drug Therap | 2001 |
The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease.
Topics: Aged; Aging; Anti-Ulcer Agents; Cisapride; Deglutition; Gastroesophageal Reflux; Humans; Hydrochlori | 2001 |
The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Cross-Over Studies; Double-Blind Method; Esophagogastric Junction; Female; G | 2002 |
Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study.
Topics: Cisapride; Cross-Over Studies; Double-Blind Method; Esophagitis; Esophagogastric Junction; Female; G | 2002 |
A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
Topics: Alginates; Aluminum Hydroxide; Antacids; Bicarbonates; Cisapride; Drug Combinations; Drug Therapy, C | 1992 |
Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux.
Topics: Alginates; Aluminum Hydroxide; Antacids; Bicarbonates; Cisapride; Drug Combinations; Drug Therapy, C | 1992 |
Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cisapride; Double-Blind Method; Female; Gastric Emptying | 1991 |
Cisapride decreases prolonged episodes of reflux in infants.
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Contents; Humans; Hydrogen-Ion Concentration; I | 1991 |
[Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms].
Topics: Antacids; Cisapride; Dose-Response Relationship, Drug; Dyspepsia; Female; Gastroesophageal Reflux; H | 1991 |
Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease.
Topics: Administration, Oral; Child, Preschool; Cisapride; Clinical Trials as Topic; Double-Blind Method; Es | 1990 |
[Treatment of chronic-obstructive upper abdominal complaints. Outlook. Further hypothetical indications].
Topics: Cisapride; Clinical Trials as Topic; Constipation; Dyspepsia; Gastroesophageal Reflux; Gastrointesti | 1990 |
Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study.
Topics: Adult; Aged; Barium Sulfate; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, | 1990 |
Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis.
Topics: Adult; Cimetidine; Cisapride; Double-Blind Method; Drug Evaluation; Esophagitis; Esophagoscopy; Fema | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
Effect of cisapride on postprandial gastro-oesophageal reflux.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Esophagus; Female; Food; Gastroesophageal Reflux; Human | 1989 |
Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH.
Topics: Administration, Oral; Cisapride; Clinical Trials as Topic; Esophagogastric Junction; Gastric Acidity | 1989 |
Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review.
Topics: Adult; Child; Cisapride; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Me | 1989 |
Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastroesophag | 1988 |
Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients.
Topics: Adult; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagogastric Junction; Female; G | 1988 |
Cisapride for gastro-oesophageal reflux and peptic oesophagitis.
Topics: Child, Preschool; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Fem | 1987 |
Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis.
Topics: Adult; Aged; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; | 1987 |
116 other studies available for cisapride and Gastroesophageal Reflux
| Article | Year |
|---|---|
Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Cisapride; Domperidone; Drug Prescriptions; Gastro | 2015 |
Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
Topics: Benzamides; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Gastrointestinal Motility; | 2008 |
Domperidone-induced QT prolongation: add another drug to the list.
Topics: Animals; Cisapride; Domperidone; Dopamine Antagonists; Drug-Related Side Effects and Adverse Reactio | 2008 |
Assessment and treatment of gastroesophageal reflux in healthy infants with apneic episodes: a retrospective analysis of 87 consecutive patients.
Topics: Cisapride; Enzyme Inhibitors; Esophageal pH Monitoring; Esophagoscopy; Female; Follow-Up Studies; Fu | 2011 |
Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Endoscopy | 2002 |
Cisapride: the black sheep.
Topics: Child; Child, Preschool; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2002 |
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chronic Disease; Cisapride; | 2003 |
CNS adverse effects of cisapride in children.
Topics: Brain; Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant; Male; Ps | 2003 |
Reflux strictures of the oesophagus in children: personal experience with preoperative dilatation followed by anterior funduplication.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Combined Modality Therapy; Dilatation; Esophageal St | 2003 |
Effect of cisapride on corrected QT interval in neonates.
Topics: Analysis of Variance; Cisapride; Electrocardiography; Female; Gastroesophageal Reflux; Gastrointesti | 2003 |
24-hour electrocardiogram before and during cisapride treatment in neonates and infants.
Topics: Arrhythmias, Cardiac; Bradycardia; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gestatio | 2004 |
[Effects of cisapride on QT interval in children].
Topics: Adolescent; Age Distribution; Child; Child, Preschool; Cisapride; Electrocardiography; Female; Gastr | 2004 |
[Stenosing gastric laryngitis in infancy].
Topics: Alginates; Cisapride; Drug Combinations; Female; Gastroesophageal Reflux; Gastrointestinal Agents; G | 2004 |
[Are prokinetic drugs still indicated for gastro-oesophageal reflux in children?].
Topics: Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans | 2004 |
Gastroesophageal reflux in children with cerebral palsy: efficacy of cisapride.
Topics: Cerebral Palsy; Child; Child, Preschool; Cisapride; Female; Follow-Up Studies; Gastric Acidity Deter | 2004 |
Long-term complications in cases of isolated esophageal atresia treated with esophageal anastomosis.
Topics: Anastomosis, Surgical; Anti-Ulcer Agents; Cisapride; Constriction, Pathologic; Endoscopy, Digestive | 1995 |
Diagnosis and treatment of gastro-oesophageal reflux.
Topics: Antacids; Child; Child, Preschool; Cisapride; Esophagoscopy; Gastroesophageal Reflux; Humans; Hydrog | 1995 |
[Drug therapy of gastrointestinal motility disorders].
Topics: Cisapride; Domperidone; Dyspepsia; Gastroesophageal Reflux; Gastroparesis; Humans; Metoclopramide; P | 1995 |
Baclofen therapy for chronic hiccup.
Topics: Anti-Ulcer Agents; Baclofen; Chronic Disease; Cisapride; Dose-Response Relationship, Drug; Female; G | 1995 |
Dystonic-like reaction following cisapride therapy.
Topics: Adult; Cisapride; Diphenhydramine; Dystonia; Female; Gastroesophageal Reflux; Humans; Parasympathomi | 1995 |
Cisapride.
Topics: Cisapride; Gastroesophageal Reflux; Humans; Piperidines; Renal Dialysis; Renal Insufficiency | 1994 |
Cisapride marketed for use in gastroesophageal reflux disease.
Topics: Cisapride; Drug Approval; Gastroesophageal Reflux; Humans; Piperidines; Serotonin Antagonists; Unite | 1993 |
[Prokinetic drugs in digestive disorders].
Topics: Antineoplastic Agents; Cisapride; Domperidone; Esophageal Motility Disorders; Gastroesophageal Reflu | 1993 |
Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy.
Topics: Adolescent; Asthma; Child; Child, Preschool; Cisapride; Esophagus; Female; Gastroesophageal Reflux; | 1993 |
Cisapride for nocturnal heartburn.
Topics: Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Gastroesophageal Reflux; Heartburn; Humans | 1994 |
Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices.
Topics: Adult; Aged; Belgium; Cisapride; Cluster Analysis; Constipation; Dyspepsia; Family Practice; Female; | 1993 |
Gastroesophageal reflux-induced cough syncope.
Topics: Adult; Cisapride; Cough; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; Male; Monitorin | 1995 |
Gastro-oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride.
Topics: Anti-Ulcer Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cisapride; Gastroesophageal Ref | 1995 |
The clinical use of cisapride in gastro-oesophageal reflux disease, with particular focus on the long-term treatment aspects.
Topics: Anti-Ulcer Agents; Cisapride; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Piperidines | 1995 |
Cisapride-induced long QT interval.
Topics: Adult; Age Factors; Bradycardia; Cisapride; Electrocardiography; Female; Gastroesophageal Reflux; Hu | 1996 |
Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children.
Topics: Anti-Ulcer Agents; Case-Control Studies; Child; Cisapride; Discriminant Analysis; Esophagogastric Ju | 1996 |
Rumination-treatment with cisapride.
Topics: Adolescent; Adult; Cisapride; Female; Gastroesophageal Reflux; Humans; Male; Parasympatholytics; Pip | 1995 |
Report from the NASPGN Therapeutics Subcommittee. Cisapride and the attack of the P-450s.
Topics: Anti-Ulcer Agents; Child; Cimetidine; Cisapride; Cytochrome P-450 Enzyme System; Drug Interactions; | 1996 |
Cisapride high dosage and long QT interval.
Topics: Cisapride; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Prem | 1997 |
Cisapride-induced prolonged QT interval: too much of a good thing!
Topics: Cisapride; Drug Overdose; Female; Gastroesophageal Reflux; Humans; Infant; Long QT Syndrome; Piperid | 1997 |
"Infantile colic" as the sole manifestation of gastroesophageal reflux.
Topics: Administration, Oral; Anti-Ulcer Agents; Cimetidine; Cisapride; Colic; Esophagus; Female; Follow-Up | 1997 |
Irritable oesophagus syndrome as cause of chronic cough.
Topics: Chronic Disease; Cisapride; Cough; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Hydrogen-Io | 1996 |
[Long QT syndrome under cisapride in neonates and infants].
Topics: Anti-Ulcer Agents; Cisapride; Dose-Response Relationship, Drug; Electrocardiography; Female; Gastroe | 1997 |
[Syncope with long QT interval in a 39 day-old infant treated with cisapride].
Topics: Anti-Ulcer Agents; Cisapride; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gastroeso | 1997 |
Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
Topics: Adult; Catheterization; Cisapride; Esophagus; Female; Gastroesophageal Reflux; Gastrointestinal Agen | 1997 |
Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Female; Gastroesophageal Reflu | 1997 |
Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
Topics: Anti-Ulcer Agents; Cisapride; Cost-Benefit Analysis; Databases, Factual; Family Practice; Gastroesop | 1998 |
Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996.
Topics: Barrett Esophagus; Bethanechol; Cisapride; Gastric Emptying; Gastroesophageal Reflux; Gastrointestin | 1998 |
Acid reflux test for gastroesophageal reflux after distal gastrectomy: diagnosis and clinical effect of cisapride.
Topics: Adult; Aged; Anti-Ulcer Agents; Barium Sulfate; Chest Pain; Cisapride; Contrast Media; Esophagitis, | 1998 |
Reflux and vocal disorders in singers with bulimia.
Topics: Adult; Anti-Ulcer Agents; Bulimia; Cisapride; Female; Gastroesophageal Reflux; Humans; Omeprazole; P | 1998 |
Gastric ulcer presenting as gastroesophageal reflux and apnea in a term neonate.
Topics: Anti-Ulcer Agents; Apnea; Cisapride; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concen | 1998 |
Cost effectiveness of treatment for gastro-oesophageal reflux.
Topics: Anti-Ulcer Agents; Cisapride; Cost-Benefit Analysis; Gastroesophageal Reflux; Histamine H2 Antagonis | 1998 |
Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride.
Topics: Cisapride; Disease Management; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Life Style; | 1997 |
Gastroesophageal reflux in children with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Female; Gastroesophageal Ref | 1998 |
Gastroesophageal reflux and pulmonary complication in a neonate.
Topics: Antiemetics; Apnea; Cisapride; Follow-Up Studies; Gastroesophageal Reflux; Gastrointestinal Agents; | 1998 |
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride; | 1999 |
Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis.
Topics: Child, Preschool; Cisapride; Drug Monitoring; Fundoplication; Gastroesophageal Reflux; Gastrointesti | 1999 |
[What are the results of medical treatments?].
Topics: Antacids; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Helicobacter Infections; Heli | 1999 |
Cisapride and caesarean section: their role in babies with gastroschisis.
Topics: Australia; Cesarean Section; Cisapride; Comorbidity; Cryptorchidism; Female; Follow-Up Studies; Gast | 1999 |
Cisapride for the treatment of gastroesophageal reflux disease in children.
Topics: Child; Child, Preschool; Cisapride; Evidence-Based Medicine; Gastroesophageal Reflux; Gastrointestin | 1999 |
[Lengthening of the QT-interval in a newborn treated with cisapride].
Topics: Cisapride; Contraindications; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infa | 1999 |
Surgical aspects of gastro-esophageal reflux disease--indication for surgery. An update.
Topics: Antacids; Anti-Ulcer Agents; Cisapride; Endoscopy, Digestive System; Fundoplication; Gastroesophagea | 1999 |
Should cisapride have been "blacklisted"?
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Cisapride; Contraindications; Electrocardio | 2000 |
Gastro-oesophageal reflux: clinical profiles and outcome.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Esophagoscopy; Female; Fundoplication; Gastroesophag | 1999 |
Respiratory symptoms and dysphagia in patients with gastroesophageal reflux disease: a comparison of medical and surgical therapy.
Topics: Cisapride; Deglutition Disorders; Female; Fundoplication; Gastroesophageal Reflux; Gastrointestinal | 1999 |
Effect of cisapride on the QT interval in infants with gastroesophageal reflux.
Topics: Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant, Ne | 2000 |
Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine.
Topics: Caffeine; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentr | 2000 |
Effect of cisapride on gastroesophageal reflux disease of children.
Topics: Adolescent; Age Factors; Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; Esophagus; Female; G | 2000 |
New safety recommendations for use of cisapride (Propulsid).
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Gastroesophageal Reflux; Gastrointestina | 2000 |
Role of cisapride in preterm infants.
Topics: Cisapride; Contraindications; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agents; | 1999 |
Drugs and disease.
Topics: Chromans; Cisapride; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Gastroesophageal Reflux; | 2000 |
The efficacy of cisapride; time to review not regurgitate.
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2000 |
The efficacy of cisapride: what is needed for digestion?
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2000 |
Gastroesophageal reflux disease: pathophysiology and pharmacology overview.
Topics: Antacids; Cisapride; Gastroesophageal Reflux; Gastrointestinal Motility; Histamine H2 Antagonists; H | 2000 |
Randomised controlled trial of cisapride in preterm infants.
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Infa | 2000 |
The use of cisapride in neonates.
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant, Newborn; Intestinal Obs | 2000 |
(In)efficacy of cisapride.
Topics: Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant | 2000 |
Update from the Canadian Dyspepsia Working Group.
Topics: Canada; Cisapride; Dyspepsia; Gastroesophageal Reflux; Gastrointestinal Agents; Heart Diseases; Huma | 2000 |
Oesophageal pH monitoring in infants: elimination of gastric buffering does not modify reflux index.
Topics: Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentrat | 2000 |
Current pediatric indications for cisapride.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Databases, Factual; Gastroesophageal Reflux; Gastroi | 2000 |
Possible interaction between cisapride and digoxin.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cisapride; Digoxin; Drug Interactions; Female; Gast | 2001 |
Gastroesophageal reflux medications in the treatment of apnea in premature infants.
Topics: Apnea; Cisapride; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant, Newborn; | 2001 |
[Current indications for cisapride].
Topics: Cisapride; Esophagitis; Gastroesophageal Reflux; Gastrointestinal Agents; Humans | 2001 |
Cisapride associated with QTc prolongation in very low birth weight preterm infants.
Topics: Arrhythmias, Cardiac; Cisapride; Dose-Response Relationship, Drug; Drug and Narcotic Control; Electr | 2001 |
[QTc interval in newborns with gastroesophageal reflux treated with cisapride and ranitidine].
Topics: Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Infant, Ne | 2000 |
Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography.
Topics: Age Factors; Case-Control Studies; Cisapride; Electrocardiography; Female; Gastroesophageal Reflux; | 2001 |
[Anorexia nervosa or somatic disease].
Topics: Adolescent; Anorexia Nervosa; Cisapride; Erythromycin; Female; Gastroesophageal Reflux; Gastrointest | 2001 |
[Nocturnal dyspnea in a young man].
Topics: Adolescent; Asthma; Bronchial Hyperreactivity; Cisapride; Diagnosis, Differential; Dyspnea, Paroxysm | 1998 |
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 2001 |
Cisapride--a word of caution.
Topics: Arrhythmias, Cardiac; Canada; Cisapride; Electrocardiography; Gastroesophageal Reflux; Humans; Risk | 2001 |
Gastroesophageal reflux in infants and children.
Topics: Child; Cisapride; Diagnosis, Differential; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gas | 2001 |
Prokinetics and reflux: a promise unfulfilled.
Topics: Cisapride; Esophagogastric Junction; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Serot | 2002 |
[The relationship between obstructive sleep apnea and gastroesophageal reflux and the effect of antireflux therapy].
Topics: Adult; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Female; Gastroesophageal Reflux; Hum | 1999 |
Cochrane's epitaph for cisapride in childhood gastro-oesophageal reflux.
Topics: Child; Cisapride; Drug and Narcotic Control; Evidence-Based Medicine; Female; Gastroesophageal Reflu | 2002 |
Cervical osteophyte induced dysphagia.
Topics: Anti-Ulcer Agents; Cervical Vertebrae; Cisapride; Deglutition Disorders; Esophageal Stenosis; Gastro | 2001 |
Changes in related drug class utilization after market withdrawal of cisapride.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cisapride; Drug and Narcotic Control; Drug Utilizatio | 2002 |
Comparison between pediatricians and family practitioners in the use of the prokinetic cisapride for gastroesophageal reflux disease in children.
Topics: Cisapride; Clinical Competence; Family Practice; Female; Gastroesophageal Reflux; Gastrointestinal A | 2002 |
[Evaluation of the effectiveness of cisapride in the treatment of gastroesophageal reflux].
Topics: Child; Child, Preschool; Cisapride; Evaluation Studies as Topic; Female; Gastroesophageal Reflux; Hu | 1992 |
Gastric emptying in infants with gastroesophageal reflux. Ultrasound evaluation before and after cisapride administration.
Topics: Cisapride; Female; Gastric Acidity Determination; Gastric Emptying; Gastroesophageal Reflux; Humans; | 1992 |
Gastroesophageal reflux: clinical presentation in two pairs of twins.
Topics: Antacids; Cisapride; Diseases in Twins; Female; Gastroesophageal Reflux; Humans; Infant; Male; Piper | 1992 |
Cisapride and gastroesophageal reflux disease.
Topics: Cisapride; Drug Therapy, Combination; Gastroesophageal Reflux; Omeprazole; Piperidines; Ranitidine | 1992 |
[24-hour esophageal pH-metry in the evaluation of gastroesophageal reflux pathology].
Topics: Antiemetics; Benzamides; Child; Child, Preschool; Cisapride; Esophagus; Female; Gastroesophageal Ref | 1992 |
Cisapride.
Topics: Cisapride; Contraindications; Drug Interactions; Gastroesophageal Reflux; Gastrointestinal Diseases; | 1991 |
New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up.
Topics: Child, Preschool; Cisapride; Cough; Cystic Fibrosis; Female; Follow-Up Studies; Gastroesophageal Ref | 1991 |
[Absence of effect of cisapride on heart rate].
Topics: Cisapride; Depression, Chemical; Female; Gastroesophageal Reflux; Heart Rate; Humans; Infant; Infant | 1991 |
Vomiting and chronic renal failure.
Topics: Administration, Oral; Cisapride; Gastroesophageal Reflux; Humans; Infant; Kidney Failure, Chronic; P | 1991 |
Mechanisms of gastro-oesophageal reflux in cystic fibrosis.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Drainage, Postural; Esophagogastric | 1991 |
Cisapride: its use in children.
Topics: Child; Cisapride; Gastroesophageal Reflux; Gastrointestinal Diseases; Gastrointestinal Motility; Hum | 1990 |
The effects of cisapride on gastro-oesophageal reflux in children with and without neurological disorders.
Topics: Acetylcholine; Brain Damage, Chronic; Cerebral Palsy; Child; Child, Preschool; Cisapride; Down Syndr | 1990 |
[Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride].
Topics: Cisapride; Esophagitis, Peptic; Female; Gastric Emptying; Gastric Juice; Gastroesophageal Reflux; Hu | 1990 |
Long-term use of cisapride (prepulsid) in premature neonates of less than 34 weeks gestational age.
Topics: Cholestasis; Cisapride; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; Piperid | 1990 |
[Effects of gastrointestinal-motility control agents on gastroesophageal reflux].
Topics: Aged; Cisapride; Female; Gastric Acid; Gastroesophageal Reflux; Gastrointestinal Motility; Humans; H | 1990 |
[The typical patient with disorder of digestive motility].
Topics: Cisapride; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux; Humans; Intestinal Pseudo-Obstructi | 1990 |
[A drive substance for the motor in digestion. Introduction].
Topics: Acetylcholine; Cisapride; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Mot | 1990 |
[Encouragement for the tired stomach. Cisapride, a specific pro-kinetic drug for upset stomach].
Topics: Acetylcholine; Cisapride; Dose-Response Relationship, Drug; Dyspepsia; Gastric Emptying; Gastroesoph | 1990 |
Treatment of gastro-oesophageal reflux and gastric stasis: new perspectives with cisapride. Proceedings of a symposium of the 13th International Congress of Gastroenterology. Rome, 6 September 1988.
Topics: Cisapride; Gastric Emptying; Gastroesophageal Reflux; Humans; Piperidines; Serotonin Antagonists | 1989 |
Effect of cisapride on esophageal pH monitoring in children with reflux-associated bronchopulmonary disease.
Topics: Bronchial Diseases; Child; Child, Preschool; Cisapride; Female; Gastroesophageal Reflux; Humans; Hyd | 1989 |
Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: treatment with cisapride.
Topics: Cisapride; Gastroesophageal Reflux; Humans; Infant, Newborn; Piperidines; Posture; Sleep Apnea Syndr | 1989 |
Gastroesophageal reflux: a primary defect in cystic fibrosis?
Topics: Child, Preschool; Cisapride; Cystic Fibrosis; Female; Follow-Up Studies; Gastroesophageal Reflux; Hu | 1988 |
Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide.
Topics: Cisapride; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Infant; Metoclopr | 1987 |
Review of the current status of prokinetic agents in gastroenterology.
Topics: Benzamides; Chemical Phenomena; Chemistry; Cisapride; Dexamethasone; Digestive System; Domperidone; | 1985 |